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Abstract
Small field dosimetry presents complications and uncertainties that could be
circumvented by using detectors which are smaller than the radiation field. This study evaluates
the reproducibility and accuracy of TLD micro-cubes for use in stereotactic radiosurgery (SRS)
remote auditing quality assurance (QA) for treatment centers participating in clinical trials. This
study tested the hypothesis that TLD micro-cubes could be commissioned to evaluate small field
dosimetry, and provide reproducibility within ±3%, as well as assure agreement between
measured dose and calculated doses to within ±5%.

The aims of this thesis were to characterize and commission TLD micro-cubes as well as

to develop guidelines for handling micro-cubes. Additionally the micro-cubes were
commissioned to evaluate standard single field output dosimetry. Further aims were to adapt
IROC Houston SRS head phantoms to use TLD micro-cubes for anthropomorphic phantom
quality assurance and to test this design on linac, Gamma Knife, and CyberKnife treatment
delivery machines. The final aim was to use TLD micro-cubes to evaluate photon fields which are
smaller than 1.25 cm in diameter.
This study was designed by first defining the handling process, including: selection of
micro-cubes, annealing parameters, and readout techniques. The micro-cubes were then
vi

characterized based on correction factors for element sensitivity, signal fading, dose response,
and energy response.
To test the reproducibility and accuracy of the dosimeters, they were first evaluated
under a single small field beam in a simple geometric configuration, then in anthropomorphic
SRS head phantoms. Agreement between calculated dose and measured dose was evaluated.
Following satisfactory results of these experiments, the micro-cubes were used to evaluate
single small fields down to 5 mm fields on the same basis as single field output checks.
TLD micro-cubes showed good accuracy and agreement when compared to beam
output, treatment planning system (TPS) dose, and measurements made with TLD powder. For
all experiments conducted in this study, measured dose was within 4.1%. For SRS experiments,
the average difference in measured and expected dose was within 3.4% with an average
difference of 1.0% and an average coefficient of variation of 0.9%. For single field experiments,
all measurements were within 4.1% with an average of 2.1% and an average coefficient of
variation of 0.6%. These results give us confidence in our ability to accurately measure dose in
radiation fields as small as 5 mm in diameter, as well as obtain excellent reproducibility.
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1 Introduction
Imaging and Radiation Oncology Core of Houston
Mission Statement
Provide integrated radiation oncology and diagnostic imaging quality control programs
in support of the NCI’s NCTN Network thereby assuring high quality data for clinical trials
designed to improve the clinical outcomes for cancer patients worldwide.
The QA programs at IROC Houston are designed to assure NCI and the NCTN Groups that
institutions participating in NCTN clinical trials deliver prescribed radiation doses that are
clinically comparable and consistent.
We accomplish this by assessing the institution’s radiotherapy programs, helping the
institutions implement remedial actions, assisting the NCTN Groups by reviewing protocols and
QA procedures, and informing the community of our findings.
1.1

Statement of the Problem
In order to advance radiation therapy treatment, it is necessary to answer a foundational

question: How can the relationships between dose to tumor and dose to healthy tissue be
maximized? Physicists continually seek better answers to this question and recent developments
of small field radiotherapy, such as those used in stereotactic radiosurgery (SRS), have partially
answered this quandary. Stereotactic radiosurgery utilizes small field photon beams to deliver a
high, conformal dose to a tumor with a sharp dose fall off in surrounding healthy tissue.
Advances in treatment delivery units such as Brainlab m3 linear accelerator (linac) with
microMultileaf Collimator (Brainlab Inc., Feldkirchen, Germany), Gamma Knife (Elekta
Instrument, Stockholm, Sweden), and CyberKnife (Accuray Inc., Sunnyvale, CA) have field sizes
1

as small as 4mm in diameter. The ability to create a highly conformal treatment plan with small
radiation fields permits the delivery of a high tumor dose in a low number of fractions: the
ideology behind SRS.
As a result of the high dose gradients of SRS treatment, small errors in treatment delivery
or dosimetry can result in increased toxicity to normal tissue, while reducing tumor control. Thus
the need for dose verification is vital to providing quality treatment (Wowra, Muacevic, & Tonn,
2009). However dosimetric challenges arise with the use of small fields. A small field is defined
as fulfilling at least one of the following characteristics: there is a loss of lateral charged particle
equilibrium on the beam axis; there is partial occlusion of the primary photon source by the
collimating devices on the beam axis; the size of the detector is similar or large compared to the
beam dimensions (Palmans et al., 2018). Both the nature of SRS treatment and the
considerations of small field dosimetry necessitate an accurate and reliable tool to verify dose
delivery plans to ensure both quality and consistency.
SRS treatment verification is particularly important in the context of clinical trials. The
Imaging and Radiation Oncology Core (IROC) Houston Quality Assurance (QA) Center provides a
simple and efficient remote audit dosimetry program for institutions participating in clinical
trials. IROC Houston uses both thermoluminsecent dosimeters (TLD) and optically stimulated
luminescent dosimeters (OSLD) in their audit programs to evaluate photon, electron,
brachytherapy, and proton beams for multiple parameters. These assessments range from
simple beam output checks to end-to-end evaluations of treatment delivery using an
anthropomorphic phantom. In this work, the anthropomorphic SRS brain phantom is of
particular interest.
2

The aim of this research is to test TLD in the form of a micro-cube (1 x 1 x 1 mm3) for
implementation into a radiotherapy audit program for small field dosimetry. This study seeks to
avoid the complications of small field dosimetry, namely partial volume averaging. Micro-cube
TLD may be able to fill this niche due to their small size relative to the fields studied.
The output measured by TLD micro-cubes is proportionally small when compared to
larger forms of TLD (rods, chips, etc.). This means that small deviations in measured signal result
in rather large deviations as a percentage of measured output, thus the accuracy and
reproducibility characteristics of TLD-100 are not necessarily expected with TLD-100 microcubes, and need to be investigated.
1.2

Background

1.2.1 Stereotactic Radiosurgery
In 1908 Victor Horsley and Robert Henry Clarke developed a stereotactic apparatus
(Horsley-Clarke frame, Figure 1) for studying the brains of monkeys (Lasak & Gorecki, 2009).
Nearly 30 years later, Earnest A. Spiegel and Henry T. Wycis were the first to apply this technique
to the human brain, and introduced stereotactic surgery in 1947 (Gildenberg, 2001). Just two
years later, Lars Leksell introduced the Gamma Knife concept, which paired a stereotactic
apparatus with radiation treatment, giving birth to stereotactic radiosurgery. Leksell treated the
first patient in 1950. Originally developed by Leksell to destroy dysfunctional loci in the brain,
stereotactic radiosurgery has become widely used for a variety of treatments with recent
advances in technology (Mathieu et al., 2008).
As previously mentioned, stereotactic radiosurgery makes use of a stereotactic
apparatus combined with high energy photon beams to irradiate a lesion in a single fraction with
3

millimeter accuracy (Kano, Niranjan, Kondziolka, Flickinger, & Lunsford, 2009). Similarly,
stereotactic radiotherapy uses the same methods, but treatment is typically delivered in
multiple fractions. SRS requires precision localization of a cranial lesion and neuroanatomy in
the reference frame of the stereotactic frame using a CT, MRI, or angiographic unit (W. Li et al.,
2016). A treatment plan is developed and a concentrated dose is delivered to the lesion with a
sharp dose fall off in surrounding healthy tissue. This dramatic dose gradient provides
substantial sparing of normal brain tissue, decreasing clinical toxicity.

Figure 1: Horsley-Clarke Frame
Used with permission from the American Association of Neurological Surgeons: “A Short History of Stereotactic
Neurosurgery”, Robert Levy, MD Figure 1

The precision treatment is made possible through a combination of beam size, patient
immobilization, and tumor localization. SRS treatments often employ multiple non-coplanar
beams or arcs converging about an isocenter. Rotation from the gantry, collimator, and
treatment table about their respective axes should coincide about a common point, creating a
4

central sphere with a radius of 1mm. The use of multiple precision beams (201 individual beams
in Gamma Knife) with various isocenters and weights permits customization of dose distribution
to the tumor shape (Flickinger et al., 1990).
In SRS treatment, defining a tumor’s location is limited by diagnostic imaging technology.
Delineation of tumor boundaries using a CT depends strongly on the resolution of the image and
the association between the macroscopic view of the lesion with the microscopic range of its
borders. The resolution of an image is limited by the size of a voxel. In the early use of SRS, typical
voxel dimensions were 0.7 mm x 0.7 mm x 1 mm, or larger, depending on the separation of
slices. Consequently, the location of a lesion could not be known better than within 1.5 to 2 mm
(Michael C. Schell, 1995).
Patient immobilization considerably reduces uncertainty in dose delivery. Conventional
external beam radiotherapy setup has been investigated using differences between simulation
and port film. These investigations determined a mean standard deviation of 3 mm in treatmentto-treatment positioning, and an average discrepancy of 5 mm in variability, for cranial
treatments. In comparison, SRS treatment can achieve a standard deviation in positional
uncertainty of 2.4 mm. This uncertainty is a combination of uncertainty in the stereotactic frame
positioning (1.0 mm), isocentric alignment (1.0 mm), CT image resolution (1.7 mm), tissue
motion (1.0 mm), and point identification (AAPM Task Group Report No. 54 Table II). The
accuracy in target alignment in two SRS studies report uncertainties of 0.2 mm - 0.4 mm in
patient position (Michael C. Schell, 1995).
SRS treatment is an intricate procedure involving multiple steps, tools, and technologies.
The radiation dose delivered is highly ablative, and requires incredible precision to ensure
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satisfactory patient outcome. Implementing SRS treatment into a clinic’s repertoire requires a
deep understanding of the importance in maintaining a stringent quality assurance program to
reach the full potential of this advanced treatment.
1.2.2 Small Field Dosimetry
The increase in use of standard multileaf collimators (MLC) and add-on MLCs has caused
a downstream effect in the availability of small static fields for radiation therapy. Additionally,
the use of small external beam radiation fields used in SRS treatments has also risen as
technology advances and treatment techniques improve. Thus, the uncertainty of clinical
dosimetry has increased as the link to conventional dosimetry practice is lost (Palmans et al.,
2018). In light of the increase in use of small field beams, it is vital that quality of treatment is
insured for patient safety and outcomes. Beam calibration and tumor localization errors as well
as machine malfunctions can have severe effects on beam output and dose delivery. When
considering that a SRS treatment can deliver 20 to 40 Gy (Schulz, Maryanski, Ibbott, & Bond,
1993) in a single fraction, any error could be severe for healthy tissue.
Differences in detector type, setup, and orientation can play significant roles in
dosimetric measurements. Detector type alone can reflect a discrepancy as large as 10%
(Godson et al., 2016). Even detector orientation can cause an overestimation in percent depth
dose at 10 cm (PDD10) of 5.7% to 8.6%. Detector positioning must be precise as just a 1 mm
deviation off central axis can influence percent depth dose (PDD) by 2% (Godson et al., 2016).
When observing dosimetric measurements between institutions, parallel inconsistencies were
noticed. For 0.6 x 0.6 cm2 fields, “the PDD at 10 cm fell outside the 95% confidence level at 63.2%
of institutions” (S. Li, Medin, Pillai, & Solberg, 2006).
6

We remember that the radiation field is defined as small when one of three
characteristics is observed: loss of lateral charged particle equilibrium (LCPE) on the beam axis;
partial occlusion of the primary photon source by the collimating device; the size of the detector
is similar or large compared to the beam dimensions (Palmans et al., 2018). Small fields are
created by collimation of flattened or unflattened photon beams using jaws, MLCs, or cones.
Because the lateral dimensions of small fields are significantly different from conventional fields,
the penumbra from both sides of the field overlap (Figure 2), which also leads to dosimetric
obstacles.
The first two conditions are characteristics of the photon beam itself. LCPE occurs when
half of the beam width is shorter than the maximum range of secondary electrons produced by
the primary photon field (Crop et al., 2009). Partial occlusion of the primary photon source is a
result the finite size of the source, which is determined by the full width half max (FWHM) of the
photon fluence profile exiting the target. The result of collimating the beam to a field size smaller
than the size of the source yields a reduced beam output on the CAX when compared to the
output of conventional fields. Partial occlusion of the photon source can have a large effect on
detector response, as it is a source of steep dose gradients and plays a role in particle spectrum
(Aspradakis et al., 2010).
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Figure 2: Partial occlusion of the primary photon source (B) causes the penumbra from both field edges
to overlap.
Aspradakis, M. M., Byrne, J. P., Palmans, H., Duane, S., Conway, J., Warrington, A. P., & Rosser,
K. (2010). IPEM report 103: Small field MV photon dosimetry. Retrieved from International
Atomic Energy Agency (IAEA), Page 7:
Copyright: Institute of Physics and Engineering in Medicine 2010. Reproduced with Permission

The third condition is a characteristic of the detector size as it pertains to the size of the
field. Generally, a detector produces a signal that is proportional to the absorbed dose over the
active volume of the detector. Therefore the detected signal is dependent on the homogeneity
of the photon field over the volume: volume averaging. This, coupled with perturbations in the
charged particle fluence caused by the presence of the detector, characterizes small fields as
those where the external edge of the detector volume is closer to the field edge than the range
for LCPE in the medium (Agency, 2017).
Small field dosimetry presents many challenges, but there are many detectors designed
for this purpose. These detectors include micro-ionization chambers, diodes, film, and solid state
detectors. An appropriate detector should be chosen for the particular application. Each has its
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own unique advantages, and some are more accurate and reliable than others. Additionally, a
great deal of precision is needed to make accurate measurements in small field dosimetry. This
can be made clear by looking at a dose profile for a 4 mm Gamma Knife photon beam (Figure 3).
We can see that there is no flat area/ plateau of dose on the central axis. We can also observe
the steep dose falloff to 90% just 2 mm off the CAX. This means detector placement or
localization must be very precise for accurate results.
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Figure 3: 4mm dose profile for Gamma Knife. See Appendix for more profiles.

1.2.3 The Imaging and Radiation Oncology Core Houston QA Center Services
The Imaging and Radiation Oncology Core (IROC) Houston, originally titled the
Radiological Physics Center, was founded in 1968. IROC Houston works with institutions
participating in National Cancer Institute (NCI)-sponsored clinical trials to monitor and evaluate
beam output, dosimetry data, calculation algorithms used for treatment planning, and quality
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control procedures (Ibbott, 2010). The key objective of IROC Houston is to insure quality of
treatment as well as congruency of treatment among institutions participating in the same
clinical trial.
These evaluations may be performed in person by an IROC Houston physicist, or it may
be performed as part of the IROC Houston remote audit program. For remote audit programs,
IROC Houston makes use of both TLD and OSLD to evaluate photon, electron, and proton beams.
Using these dosimeters, IROC Houston monitors more than 22,600 megavoltage photon and
electron beams from 2100 institutions each year. Although OSLD has become the predominate
dosimeter, IROC Houston continues to use TLD in their QA programs.
Institutions participating in NCI-sponsored clinical trials using photon beams are
monitored on a yearly basis, while electron beams are monitored on a 2-year cycle. For each
institution and each radiation beam, an acrylic mini-phantom containing either TLD or OSLD is
mailed. The dimensions of the phantom are specific to the beam being evaluated and range from
3 x 4.5 x 1.5 cm3 to 6.5 x 6.5 x 5.5 cm3 for photon beams and 8.5cm cubes for electron beams.
Each phantom is designed to produce electronic equilibrium for photon beams and full phantom
scatter for electron beams. IROC Houston also uses anthropomorphic phantoms for more indepth analysis of treatment plans. These phantoms include head (Figure 4), spine, liver and lung,
and are generally used as an end-to-end test of the entire treatment process: CT simulation,
treatment planning, and treatment delivery.

10

Figure 4: IROC SRS Head Phantom

The dosimetry auditing program implemented by IROC Houston performs quite well.
With regards to TLD, the uncertainty in dose determination for TLD-100 is 1.3% at one sigma
level (Alvarez, Kry, Stingo, & Followill, 2017). IROC Houston currently uses TLD-100 powder in
capsules for dosimetry measurements (Figure 5). These capsules are placed within phantoms for
various QA audits. IROC Houston plans to incorporate TLD-100 micro-cubes into their existing
audit program, in hopes to evaluate small field sizes that are currently beyond the limitations of
their TLD capsules.
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Figure 5: Capsules used to contain TLD-100 Powder.

1.2.4 Thermoluminescent Dosimeters
1.2.4.1 Introduction to Thermoluminescent Dosimeters
TLD are crystals which contain added impurities that can be used to trap electrons in
energetic states which can be released through thermal stimulation to produce fluorescent
photons. In the realm of dosimetry, TLD have been commonplace for nearly a century.
Thermoluminescence was noted by Sir Robert Boyle and Henri Becquerel long before it was used
in dosimetry. In 1904, Marie Curie observed the thermoluminescent properties of calcium
fluoride (CaF) after exposure to radium. Many years later, Sir John Turton Randall and Maurice
Wilkins developed a theory of thermoluminescent dosimetry by interpreting characteristics of
measured glow curves (Kron, 1995).
Although one of the first uses of TLD was for archeological and geological dating,
Farrington Daniels theorized various applications, including clinical dosimetry using lithium
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fluoride (LiF). The first application to clinical dosimetry involved a patient swallowing a crystal,
post injection of radioactive isotopes. Upon recovery, the TLD were gauged for accumulation of
dose in roentgens, by measuring luminescent intensity. For many years, TLD use in medical
dosimetry was not widespread. This was part in due to the stumbling blocks of TLD, namely
energy dependence, fading, and ultraviolet light sensitivity. James Cameron, however, was later
able to demonstrate importance of added impurities, leading to more efficient dosimeters.
Cameron, along with Harshaw Chemical Co., developed TLD-100 (LiF:Mg,Ti), which is the most
commonly used TLD.
LiF can be produced in various forms, including a single crystal; however, these crystals
can display significant variations in sensitivity. Therefore, LiF is often ground into powder crystals
of 100 µm in diameter. This can be utilized in powder form, or pressed into chips, rods, discs, or
cubes (Table 1). TLD are compact and easily transported, they have a wide range of sensitivities,
and are useful for doses of a few milligray to many gray. Additionally, LiF is nearly tissue
equivalent (Zeff=8.2) (Kron, 1995), which makes it suitable for in vivo dosimetry and other
patient/personnel related measurements.
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Table 1: Various commercially available forms of TLD-100 from ThermoScientific™.

Thermo Scientific™ TLD-100 Dimensions
Shape
Rod

Diameter: 1 x 6 mm, Diameter: 1 x 3 mm, Diameter: 1 x 4
mm, Diameter: 1 x 4 mm, Diameter: 1 x 2 mm

Micro-cube

1 x 1 x 1 mm

Chip

3.2 x 3.2 x 1.5 mm, 3.2 x 3.2 x 0.38 mm, 3.2 x 3.2 x 0.89
mm, 6.35 x 6.35 x 0.89 mm

Disk

Diameter:3.6 x 0.25 mm, Diameter 3.6 x 0.38 mm

1.2.4.2 Mechanisms of Thermoluminescence
TLD operate on principles similar to inorganic scintillating crystals, which emit prompt
fluorescence after absorbing energy from an external source. To explain this property of
inorganic crystals, we must first look at the crystal lattice. Within the crystal lattice are two
energetic bands, the valence band and the conduction band (Figure 6). The valence band
contains electrons in a low energy state, and thus is mostly occupied. Electrons contained in the
valence band are inherently bound to lattice sites and are considered immobile. The conduction
band is conversely a high energy state that is sparsely occupied by electrons which are free to
migrate through the crystal lattice. There is also a third level of the crystal lattice, the band gap,
otherwise known as the forbidden band gap. Electrons are mechanically forbidden from residing
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within the band gap, and consequently must exist within the conduction band or the valence
band (Knoll).
When an electron, bound in the valence band, absorbs sufficient energy, it can be excited
up across the band gap into the conduction band. The electron leaves a “hole” behind in the
valence band. When excited electrons lose energy, they fall back down to the valence band, and
recombine with a hole, which causes an emission of a photon. In pure crystal, the energy
difference between the valence and conduction bands is large, and emitted photons lie outside
of the visible range. This result leads to the practice of intentionally adding impurities to the
crystal called activators. Activators alter the energy band structure of the inorganic crystal,
creating energy states within the forbidden gap which excited electrons may occupy (Figure 6).
Because these energy states are lower energy than the conduction band, the emitted photons
from recombination events are predictably lower energy and within the visible photon range
(Knoll).
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Figure 6 : The crystal lattice contains two energy levels of importance: the valence band, and the conduction band. The valence
band is low energy, and electrons contained in the valence band are bound to the lattice. Electrons in the higher energy
conduction band are free to migrate about the crystal lattice. In between is the band gap, in which electrons are forbidden to
occupy. Added impurities create activator sites in the forbidden band gap, which permit electron occupation.

An important note is that the inorganic crystals create prompt fluorescence. In other
words, the excitation of an electron and systematic emission of a photon happen in rapid
succession; this is where TLD differ. TLD are inorganic crystals with added impurities similar to
the inorganic crystals previously mentioned, however, the impurities added to TLD perform a
very different function. The impurities, such as Magnesium in TLD-100 (400 ppm), create
trapping centers (Figure 7) in the band gap of the crystal lattice (Knoll).
When an electron is excited up to the valence band, and falls back to the conduction
band, there is a probability that the electrons will become trapped in one of the many trapping
centers in the band gap. The advantage of trapping electrons in the band gap is that they are
stored in the trapped state until sufficient energy is added to the TLD to free them. Once freed
from the trapping center, electrons can recombine with holes, which can be trapped and freed
in a similar way, and it is this recombination which emits photons in the visible spectrum. It is
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worth noting that the Titanium (8 ppm) added to TLD-100 provides luminescent recombination
centers at which freed electrons/holes recombine accompanied by emission of a photon.

Figure 7: The impurities added to TLD provide electron/hole trapping centers in the band gap. Trapping centers permit the
use of TLD as a dosimeter that can be read out at a later time after irradiation. Trapping centers have different escape energies
(depth), and are therefore cleared at different temperatures upon readout.

In the practice of medical physics dosimetry, TLD can be irradiated, providing the external
energy necessary to jump electrons from the valence to the conduction band, leading to trapped
electrons/holes in the band gap. As dose is absorbed by the TLD, more electron/hole traps are
filled. In this way, a relationship between the number of trapped electron/hole pairs and
absorbed dose can be established. To measure the number of electron hole pairs, the TLD is
thermally stimulated to release the electrons and holes from their traps leading to
recombination events. The photons released from recombinations can be measured by a
photomultiplier tube, converting photons to a charge.
A few characteristics of TLD are fading, dose dependence, energy dependence, and
annealing. Fading refers to a concept in which electrons contained in low energy traps have a
high probability of escaping due to low energy thermal stimulation such as room temperature,
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this results in a rapid fall-off of TLD signal shortly after irradiation. Dose dependence is a
relatively evident concept; as higher dose is absorbed by the TLD, more electron hole pairs are
created, and more photons are released upon readout. TLD-100 have a linear dose response
from about 100 µGy out to 4 Gy, above this dose, response becomes supralinear (Figure 8).
Energy dependence refers to the response of TLD-100 as a function of photon energy, where we
use 1.25 Mev Cobalt 60 gammas as a reference.
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Figure 8: TLD-100 is linear out to about 400cGy; where there is an over-response as dose increases.

The last TLD concept is annealing. Annealing can be described as clearing all electron and
hole traps in the crystal lattice through a heating cycle. Not only does annealing clear these traps,
it also plays a role in the arrangement of trap levels within the forbidden gap, therefore, the TLD
response is dependent on the annealing process and should be kept consistent. Literature also
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shows that TLD sensitivity may decrease over time with continued irradiation and annealing
(Ogunleye, Richmond, Cash, & Jones, 1987).
1.2.4.3 TLD-100
TLD-100 is the most commonly utilized TLD crystal and, consequently, has been well
characterized in the literature. Many of these characteristics have been previously mentioned,
but will be concentrated on TLD-100 in this section. TLD-100 is a LiF crystal with impurities of
Magnesium (400 ppm) and Titanium (8 ppm). In the case of TLD-100, Magnesium creates the
trapping centers in the forbidden gap, and the Titanium creates the recombination centers,
which leads to photon production.
The near tissue equivalence of TLD-100 as well as the clinically relevant range of
sensitivities for both dose and energy has made it a popular personnel and in vivo dosimeter.
The effective atomic number of TLD-100 has been cited as 8.2 by Kron et al. and more precisely
as 8.27 by Taylor et al. TLD-100 is linear out to about 4 Gray where it begins to over-respond as
dose increases. If Cobalt 60 is taken as the reference energy, TLD-100 energy correction factors
are generally not larger than 7% for megavoltage beams. TLD-100 are also reliable in terms of
reproducibility and accuracy; uncertainty in dose determination is 1.3% at the one sigma level
based on IROC Houston evaluations (Alvarez et al., 2017).
Several companies have made TLD-100 commercially available. Harshaw Chemical Co.,
perhaps the most well-known company, was the first to formulate the dosimeter in the 1960’s
with the help of James Cameron (DeWerd, 1983). Today, Harshaw TLD-100 is offered for
purchase through ThermoFisher Scientific in numerous configurations.
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1.3

Hypothesis and Specific Aims

1.3.2 Hypothesis
The hypothesis developed for this experiment is stated:
Micro-cube TLD can be commissioned to evaluate small field dosimetry, and provide
reproducibility within ±3%, as well as assure agreement between measured dose and calculated
doses to within ±5%.
1.3.2 Specific Aims

1. Characterize and commission TLD micro-cubes and develop guidelines for the handling
process of TLD micro-cubes.
a. Define readout technique
b. Define annealing technique
c. Determine Elemental Correction Factor (ECF)
d. Determine Linearity, Energy, and Fading correction factors
2. Commission the TLD micro-cubes for standard single beam small field output dosimetry.
a. Develop capsule inserts which allow identification of TLD micro-cubes
b. Develop a method for making standard measurements in Cobalt 60 beam
3. Adapt the IROC Houston SRS phantom to use the TLD micro-cubes for anthropomorphic
phantom quality assurance, test the phantom using standard linac, GammaKnife and
CyberKnife treatment delivery machines, and compare the measured and calculated doses
to determine agreement and precision.
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a. Develop capsule inserts for anthropomorphic head phantom which allow
identification of TLD micro-cubes
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2 Materials and Methods
2.1 TLD Micro-Cubes
In order to avoid the dosimetric complications of partial volume averaging, a
consequence of small field dosimetry, the detector needs to be sufficiently small. The detector
type should also be well understood, and well documented in literature. This section will
highlight some detector considerations with regards to the needs of this study.
There are many detectors suitable for small field dosimetry that can provide accurate
and reliable data for radiotherapy dosimetry. These range from passive detectors like TLD,
radiophotoluminescence detectors, and alanine to active detectors such as liquid filled ion
chambers, diamond detectors, and diodes. However, because this study is focused on
developing a remote radiotherapy QA program for small field dosimetry, the detector needs to
be carefully chosen.
The detector, used for remote audtis, will be shipped to and from clinics, therefore it
would be beneficial if it was free of wires or electronics. It is preferable to use a passive detector
so that dose information is stored and can be read back at IROC Houston, eliminating any
requirement for the irradiating institution to play a role in readout. Additionally, the detector
type should be robust; environmental stressors such as heat (within the range of shipment
temperatures) and humidity should not have a degenerative impact on the performance of the
detector. In a similar sense the detector will be implemented into an audit program, so the
readout should be simple to perform.
An essential idea behind this experiment is to develop a small field audit program that is
both accurate and reproducible within the standards set in place at IROC Houston. That is, the
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dosimeter should exhibit reproducibility within ± 3%, showing reliability of a measurement.
Additionally, the dosimeter should be accurate to within ± 5% when comparing the TLD
measured dose to the treatment planning system (TPS) calculated dose.
TLD-100 micro-cubes (Figure 9) display characteristics that satisfy the requirements
determined by the nature of the service to be provided. They are sufficiently small (1 x 1 x 1
mm3), where the smallest field size to be evaluated is 4 mm in diameter, therefore partial volume
averaging correction factors are minimized. In terms of reliability, Regulla et al (da Rosa, Regulla,
& Fill, 1999) was able to achieve a mean reproducibility of 1.03% in one standard deviation,
which is well within the ± 3% objective.
These passive detectors are well understood, can be reused multiple times, and can be
easily transported. TLD-100 is the original dosimeter through which IROC Houston’s services
were developed, and implementing micro-cubes into the workflow of IROC Houston should be
a smooth transition.

Figure 9: Harshaw TLD-100 Micro-Cubes from ThermoScientific
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2.1.1 TLD-100 Micro-Cube Specifications
Dimensions: 1 x 1 x 1 mm3
Material: LiF:Mg,Ti
Zeff: 7.51 (Azangwe et al., 2014)
Density: 2.64 g/cm3
Electron Density (relative to water): 0.833 e-/g
Accuracy: ± 15% (± 2 sigma)
Emission Spectra: 3500 to 6000 Å
Measurement Range: 10 pGy to 10 Gy

2.2 TLD Micro-Cube Handling
2.2.1 Micro-Cube Shape Uniformity
In order to obtain satisfactory reproducibility and accuracy, certain measures were taken
in preparing TLD-100 micro-cubes for use in an audit program. Despite the name, the microcubes are not perfectly cuboidal, and each face is not necessarily a smooth surface. To reduce
the likelihood of poor reproducibility, each micro-cube was carefully inspected.
Shape uniformity was an obvious characteristic to keep in mind when inspecting
individual cubes. Aspects such as chipped edges or apparent cracks in the crystal were checked
and irregularly shaped cubes were removed from service. The color of the cube was also
inspected. In this study, some cubes with a yellowish opaque color exhibited poor dosimetry
performance. Although discoloration did not appear to affect the signal stability, these cubes
had significantly lower response to radiation, and were not suitable for audit use.
24

Moreover, throughout the course of the experiment, a handful of other detectors were
determined to be of poor uniformity and were discarded or discontinued. This included some
micro-cubes which had a uniform shape and no apparent physical distortion, but did not produce
reliable signal. These steps were important in characterizing and commissioning TLD, as one
cannot assume that all micro-cubes will provide the same reproducibility.
2.2.2 TLD Annealing
Annealing refers to the process of clearing electron and hole traps in the crystal lattice
through heating cycles. The annealing process is to be performed before irradiation, which
allows the dosimeter to be reused multiple times. If the dosimeter is expected to respond the
same after each annealing cycle, then the cycle should be identical each time it is performed.
The annealing methods used in a TLD dosimetry system need to be well defined, and well
implemented.
This experiment followed the guidelines developed by Cameron et al. (Grant & Cameron, 1966):
1. 1 hour and 20 minutes at 400oC
2. 5 minutes rapid cooling between aluminum cooling plates
3. 2 hours at 100oC
For annealing procedures, the micro-cubes were contained within a Radiation Products
Design, Inc. aluminum TLD chip annealing planchet (Figure 10). For heating to 400oC, a Radiation
Products Design Inc. Model 168 TLD Annealing furnace (Radiation Products Design Inc.,
Albertville, Minnesota) (Figure 11) was used. For heating the micro-cubes to 100oC, a Blue M
Electric Company Stabil-Therm Gravity Oven (Thermal Product Solutions, New Columbia,
Pennsylvania) (Figure 12) was used. To rapidly cool the annealing planchets between heating
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cycles, two aluminum plates were used. The plate dimensions were approximately 14 x 16 x 1
cm3.

Figure 10: Radiation Products Design Inc. annealing planchet

Figure 11: Radiation Products Design Inc. Model 168 TLD Annealing Furnace
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Figure 12: Blue M Electric Company Stabil-Therm Gravity Oven

TLD annealing can have a profound effect on TLD output. To test the sensitivity of the
annealing procedure, we tested the TLD response from 500 cGy of absorbed dose using different
annealing techniques, and compared them to our standard. The times we tested are in Table 2.
The purpose of this test was to expose dependencies on annealing times that may be used as
part of human error.
To help define the cooling portion of the annealing cycle, we measured the temperature
of the aluminum planchet as a function of time during the five minute cooling period. To make
these measurements, an infrared thermometer was used. The aluminum planchet was heated
to 400oC, and then placed between the two room-temperature aluminum plates. The room
temperature was 20.5°C. . Measurements were then made at various time intervals after
removal from the oven. These measurements were repeated multiple time until a consistent
trend in the temperature change was measured.
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Table 2: TLD annealing times

Annealing Trial

Time at 400oC

Rapid Cooling Time

Time at 100oC

Baseline

1 hour 20 minutes

5 minutes

2 hours

Trial 1

1 hour 30 minutes

5 minutes

2 hours

Trial 2

1 hour 20 minutes

3 minutes

2 hours

Trial 3

1 hour 20 minutes

5 minutes

2 hours 30 minutes

Trial 4

1 hour 20 minutes

0 minutes

2 hours

2.2.3 TLD Signal Reading
To get signal from TLD, external energy needs to be supplied to free the electron and
hole traps. This allows for the process of recombination describe in section 1.2.4.2 which
releases a photon. To get dose from the TLD, the number of photons released through the
reading heating cycle needs to be known, so a photomultiplier tube is coupled to the heating
mechanism. This converts photons released to a charge which can then be related to an
absorbed dose. Usually, when TLD in powder form are used, the amount of powder irradiated is
weighed so a relationship between charge and mass (Coulombs/gram) can be used to relate
charge to dose. Because this experiment uses an ECF, knowing the mass of each cube is
unnecessary.
The reader used to evaluate the glow curve (Figure 13) of the TLD micro-cubes was a
Harshaw model 3500 manual TLD reader (ThermoFisher Scientific, Weltham, Massachusetts).
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Although use of the Harshaw 3500 is somewhat labor intensive, when compared to the Harshaw
5500, there is reason to believe the Harshaw 5500 may not be the optimal machine for
evaluation of TLD micro-cube signal. A study conducted by de Rosa et al. demonstrated a
reproducibility of 3.27% using the Harshaw 5500 automatic reader, and a reproducibility of
2.47% using the Harshaw 3500 manual reader, a significant improvement where all other factors
remained constant.

Figure 13: Glow curve captured from TLD-100 micro-cube using Harshaw reader and WinRems software

The software used to read TLD micro-cube signal was WinREMS (ThermoScientific). This
software allowed us to define a heating curve for reading TLD micro-cubes which is outlined in
Table 3.
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Table 3: WinREMS software TTP parameters for reading TLD micro-cubes

Parameter

TTPs

Preheat Temp (oC)

50

Preheat Time (sec.)

0

Acquire Rate (oC/sec.)

10

Acquire Temp (oC)

300

Acquire Time (sec.)

33+1/3

Anneal Temp (oC)

300

Anneal Time (sec.)

0

Because micro-cubes have non-uniform faces, the thermal contact with the heating
planchet is slightly different on each face. Therefore, to maintain consistency, the same face of
each cube should be read each time signal is measured. This precaution can reduce variation in
reproducibility from 4% to 0.9% as demonstrated by Bassinet et al. (Bassinet et al., 2010). A
similar study also showed that establishing a reading face of the cube can improve
reproducibility from 2.47% to 1.03% (da Rosa et al., 1999).
Bassinet also took the following precaution in maximizing reproducibility: “the microcube must be positioned with good reproducibility on the heating system (planchet)” (Bassinet
et al., 2010). This is difficult to do as the Harshaw 3500 reader used only has a planchet designed
for TLD chips (Figure 14). The dimensions of the reading area of the planchet are approximately
1 cm x 1 cm2. The only way to achieve reproducible placement is to guide-by-eye the placement
of the micro-cube in the center of the heating planchet using fine point tweezers. This certainly
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comes with some uncertainty in placement and is likely user dependent, however, alteration to
the surface of the heating planchet could come with consequences in heating or luminescence
of the aluminum itself, and it was not desirable to take that risk.

A

B
Figure 14: A) Harshaw 3500 TLD annealing planchet B) TLD Micro-cube in the center of the heating planchet

To investigate how TLD placement on the reading planchet might affect TLD micro-cube
reproducibility, the micro-cube were read without taking significant care in placing the cube in
the center of the reading area. This meant some TLD micro-cubes were placed on the
edge/periphery of the central reading area, and some were placed closer to the center. In
general, the only criteria followed for this test was placing the cube inside of the 1 cm x 1 cm
reading area. This gave some insight into the care that is needed in placing the micro-cube in a
reproducible location.
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2.3 TLD Micro-Cube Characterization
There are many corrections to the TLD signal that must be applied to get dose. These
correction factors account for the absorbed dose response, the energy of the photon beam, the
time between irradiation and reading, and the sensitivity of the entire reader system. In defining
these parameters, the TLD are characterized, and can then be used as dosimeters.
The dose absorbed by the reference medium at the location of the micro-cube can be
calculated using Equation 1 and Equation 2 (Kirby, Hanson, & Johnston, 1992). Thus, the
characterization of TLD micro-cubes entails defining each correction and calibration factor.
𝐷𝐷 = 𝑇𝑇𝑇𝑇𝐾𝐾𝐿𝐿 𝐾𝐾𝐹𝐹 𝐾𝐾𝐸𝐸 ECF

Equation 1

D= absorbed Dose to the reference medium at the location of the TLD
T= thermoluminescence reading (nC)
S= system calibration factor (cGy/nC)
KL=dose response linearity
KF=fading correction factor
KE=energy correction factor
ECF= elemental correction factor
Prime (‘) denotes reference conditions

𝑺𝑺 =

𝑫𝑫′
𝑻𝑻′𝑲𝑲𝑭𝑭′ 𝑲𝑲𝑳𝑳′
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Equation 2

2.3.1 Elemental Correction Factor
TLD micro-cubes have relatively non-uniform response on a cube-to-cube basis. This can
be expected from a batch of micro-cubes, as each cube is unique on a microscopic and
macroscopic level.

Although the signal from one cube to the next is inconsistent and

unpredictable, a single cube can be expected to produce the same response from a given dose.
This leads to the establishment of an elemental correction factor (ECF). ECF (Equation 3) is
defined as the average signal of a group of TLD micro-cubes, irradiated to the same dose, divided
by an individual cube’s signal.

𝐸𝐸𝐸𝐸𝐸𝐸 =

𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 (𝑛𝑛𝑛𝑛)
𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼 𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 (𝑛𝑛𝑛𝑛)

Equation 3

The ECF gives insight as to how an individual micro-cube responds in relation to a batch
average of micro-cubes. This batch, population, or group, must be maintained and micro-cube
identity within the group must remain known, otherwise, ECF must be re-calculated. These
groups should be annealed, irradiated, and read together, so that there is no discrepancy in the
annealing cycle, irradiation technique, or reading sensitivity. These are requirements in
obtaining reliable ECF values during the characterization and commissioning of TLD micro-cubes.
To establish ECFs for micro-cubes, the following steps were taken:
1. Micro-cubes were annealed
2. Micro-cubes were irradiated to 500 cGy using a Cobalt 60 source
3. Micro-cubes were allowed a minimum of 48 hours to fade
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4. Micro-cubes signals were measured in a single session using a Harshaw 3500
5. Measurements were repeated for a total of 3 data sets to establish an average ECF
value
For this experiment, we had 5 groups of TLD micro-cubes; 4 groups of 100 and 1 group
of 63. An ECF value was measured for each cube in each group three times, where the average
was taken across a group. This gave us three measurements to evaluate and allowed us to check
TLD reproducibility on a macroscopic level and discard TLD which showed large coefficients of
variation (Equation 4).

𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝑜𝑜𝑜𝑜 𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉 = 100% ×
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𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷
𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴

Equation 4

A

B

Figure 15 A) ECF irradiation disc B) Irradiation disc with buildup.

Rotating irradiation discs were used to ensure uniform dose delivery among the microcubes. The discs are made of acrylic and are centered on the CAX of the 24.5 cm x 24.5 cm Cobalt
beam at 80.5 cm (SSD). The ring of cubes sits 5.8 cm from the center of the disc, which slowly
rotates beneath the beam during the radiation exposure, ensuring that all TLD are exposed to
the same dose, i.e. this reduces effects of any possible hotspots in the field. The buildup is 5.65
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mm thick, providing electronic equilibrium for the 1.25 MeV 60Co photons at the depth of the
micro-cube (Alvarez et al., 2017).
2.3.2 System Calibration Factor: S
𝑆𝑆 =

𝐷𝐷′
𝑇𝑇′𝐾𝐾𝐹𝐹′ 𝐾𝐾𝐿𝐿′

The calibration factor, which can also be described as the system sensitivity, accounts for
changes in reader electronics, optics, planchet characteristics, and heating properties (Kirby et
al., 1992). “The system calibration factor is defined as the inverse of the thermoluminescence
response of the TLD system per unit dose “(Kirby et al., 1992). Therefore, in Equation 2, D’, T’,
KF’, and KL’, the prime (‘) denotes values obtained from the standards.
IROC Houston uses 300 cGy as the dose for the standards, delivered with a

60Co

unit.

However, for this experiment, we used both 300 cGy and 600 cGy as standard doses. Because
the dose delivered to the TLD micro-cubes for SRS head phantom audits will be doses closer to
600 cGy, we made our standards closer to that dose to reduce uncertainty in the correction
factor used. For these experiments, standards were irradiated on the same day of single field
irradiations (Section 2.4) and SRS head phantom irradiations (Section 2.5). Doing the standard
irradiations on the same day as the experimental irradiation allowed fading corrections to be
ignored.
To irradiate standards in a

60Co

beam, we used an acrylic “mini-phantom” (Figure 16)

that was originally constructed for OSLD irradiations, but was adapted for micro-cubes. The
acrylic mini-phantom is 4.5 x 3 x 1.6 cm3. The micro-cubes sat inside of the mini-phantom under
a 6.8 mm buildup cap, providing Dmax at the location of the TLD. The geometry of these
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irradiations was a 10 cm x 10 cm field at 79.3 cm SSD. These conditions were defined to deliver
a known dose to the TLD.

Figure 16: IROC Cobalt mini-phantoms
4.5 x 3 x 1.6 cm3, 6.8 mm buildup cap, TLD micro-cube numbered insert for cube identification.

2.3.3 Linearity Correction: KL
The linearity correction factor relates the signal measured to the dose absorbed by the
TLD. We expect the dose and the signal to be proportional, and in general this is a true statement
for TLD-100, up until about 400 cGy. Beyond this dose, the signal begins to over-respond as dose
increases, as displayed in Figure 8. To make these measurements, we used the same rotating
irradiation disc from the ECF irradiations under the same configuration, using the 60Co beam to
deliver the doses.
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To make these measurements, we used 2 micro-cubes per dose level, with 2 sets of
system sensitivity standards irradiated to 300 cGy; one at the beginning and end of each reading
session. We repeated this linearity experiment once. The doses used to evaluate linearity were:
100 cGy, 200 cGy, 300 cGy, 500 cGy, 600 cGy, 700 cGy, 1000 cGy. This range of doses gave us a
clear picture of how the TLD respond to dose over a wide range, including the supralinear region.
The maximum dose used, 1000 cGy, is considered the limit for TLD micro-cubes, as the overresponse of the micro-cubes is too significant and requires a large correction factor.
The linearity correction for a given measurement is defined in Equation 5. The raw dose
is defined as the reading, in coulombs, from a micro-cube multiplied by the system sensitivity,
ECF and fading correction factors (Equation 6). In this experiment, fading was taken to be unity.

𝐾𝐾𝐿𝐿 = 𝑚𝑚(
m=slope

1
) ∙ 𝑟𝑟𝑟𝑟𝑟𝑟 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑(𝑐𝑐𝑐𝑐𝑐𝑐) + 𝑏𝑏
𝑐𝑐𝑐𝑐𝑐𝑐

b=intercept
Equation 5: Linearity correction factor

SS=system sensitivity

𝑐𝑐𝑐𝑐𝑐𝑐
𝑅𝑅𝑅𝑅𝑅𝑅 𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷 = 𝑇𝑇(𝑛𝑛𝑛𝑛) ∙ 𝑆𝑆𝑆𝑆 �
� ∙ 𝐸𝐸𝐸𝐸𝐸𝐸 ∙ 𝐾𝐾𝐹𝐹
𝑛𝑛𝑛𝑛

ECF=elemental correction factor
T= reading in (nC)
Equation 6: Raw Dose
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2.3.4 Energy Correction Factor: KE
𝐾𝐾𝐸𝐸 =

𝐷𝐷𝐷𝐷′
𝐷𝐷′𝑇𝑇

Equation 7: Energy Correction Factor

The energy correction factor was used to correct the thermoluminescent response of
TLD for different energies, with

60Co

as a reference in Equation 7. The energies used for this

correction factor were 60Co (which defines the reference energy) and 6 MV.
For the

60Co

reference, the same conditions for irradiating standards for system

sensitivity in section 2.3.2 were held. For this reference, 600 cGy was delivered to the standards.
To make these measurements, we used a 15 x 15 x 19 cm3 high impact polystyrene
phantom with capsules containing TLD micro-cubes. Each capsule held 3 TLD micro-cubes, and
the phantom held one capsule at 10 cm. The 6 MV photon beam from a Trilogy linear accelerator
(Varian Medical Systems, Palo Alto, California) was used. Prior to irradiating the TLD for energy
correction measurements, the Trilogy beam was calibrated following the guidelines of TG-51
(Almond et al., 1999). The beam calibration in water was cross-referenced with the beam output
at 10 cm depth in the polystyrene phantom used for the energy correction. 600 MU were
delivered for a 10 x 10 cm2 field. Three irradiations were conducted. For each measurement, the
signal per unit dose was evaluated and divided by the signal per unit dose for 60Co.
2.3.5 Fading Correction Factor: KF
The fading correction factor is used to correct the thermoluminescence for low energy
traps that may be cleared at room temperature during the time between irradiation and reading.
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The fading correction factor is necessary when there is no pre-read annealing to clear these
shallow traps or low temperature peaks. The correction is also needed when standards and
samples are irradiated on different dates. For this experiment, standards were always irradiated
and read on the same day as the sample, so fading correction was not necessary.
When this system is implemented as an IROC Houston audit program, a fading correction
curve must be established if standards and phantom irradiations are conducted on different
days. To make these measurements, TLD micro-cubes would be irradiated at given intervals prior
to a designated date, on which all TLD from each irradiation session would be read for signal. It
is important to read all TLD on the same day so that the system sensitivity correction is the same
for all cubes. A fading correction curve should be established for approximately three months to
cover a wide range of delays between the irradiation date and the read date.

2.4 Uncertainty Analysis
The uncertainty in determining the dose to TLD micro-cubes needs to be assessed in
order to have confidence in their measurements. The guidelines presented by Kirby et al. were
followed in assessing the uncertainty of the data collected in this experiment. Because dose to
TLD is determined using Equation 1, below, the uncertainty in the constituents of the equation
need to be established individually and summed in quadrature. Therefore, the uncertainty to
the dose as calculated from the TLD reading is defined in Equation 8 (Kirby et al., 1992).
𝐷𝐷 = 𝑇𝑇𝑇𝑇𝐾𝐾𝐿𝐿 𝐾𝐾𝐹𝐹 𝐾𝐾𝐸𝐸 ECF
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Equation 1

𝑠𝑠𝐷𝐷2 = (𝑠𝑠𝑇𝑇

𝛿𝛿𝛿𝛿 2
𝛿𝛿𝛿𝛿 2
𝛿𝛿𝛿𝛿 2
𝛿𝛿𝛿𝛿
𝛿𝛿𝛿𝛿 2
𝛿𝛿𝛿𝛿
𝛿𝛿𝛿𝛿 2
) + (𝑠𝑠𝐷𝐷′
) + (𝑠𝑠𝐸𝐸
) + (𝑠𝑠 𝑇𝑇 ′ ′ )2 + (𝑠𝑠𝐹𝐹
) + (𝑠𝑠𝐿𝐿 )2 + (𝑠𝑠𝐸𝐸𝐸𝐸𝐸𝐸
)
′
𝛿𝛿𝛿𝛿
𝛿𝛿𝐷𝐷
𝛿𝛿𝐾𝐾𝐸𝐸
𝛿𝛿𝑇𝑇
𝛿𝛿(𝐹𝐹)
𝛿𝛿𝛿𝛿
𝛿𝛿𝛿𝛿𝛿𝛿𝛿𝛿

Equation 8

Here the subscripts, T and T’ denote the thermoluminescent reading from the TLD, D’ is
the dose to the standards, D is the dose to the sample, KE is the energy correction factor, F is the
fading correction factor, L is the linearity correction factor and ECF is the elemental correction
factor. Together, sD defines the uncertainty in a single dose calculation. For each of these terms,
a value for the uncertainty was established, and a final value for the entire system was obtained.
For this experiment, the uncertainty in fading was not evaluated.

2.5 Single Field Irradiations
Single small field irradiations are used to check beam output under a simple geometric
configuration for 6 MV photon beams. This test serves to assess beam output alone at different
field sizes, and is not meant to evaluate the treatment planning process of a clinical trial.
IROC Houston uses a polystyrene block phantom (Figure 17 and Figure 18) (dimensions:
14.8 x 14.8 x 16.5 cm3) with a cylindrical phantom insert (Figure 19) (dimensions: radius: 7.5 cm,
height: 8.3 cm) to evaluate linac beam output. The cylinder and block contain a fitting thread,
indicated by the arrow in Figure 18A and Figure 19A, to ensure that the cylinder is oriented the
same way each time. The phantom insert holds two TLD capsules: one at Dmax and one at a depth
of 7 cm. Both capsules are in the center of the cylinder, indicated by the arrow in Figure 19B.
Above the first capsule is a slit in the phantom which holds GAFchromic film (Figure 19C). The
film allows us to check the CAX alignment and dose profile. The film also has pin-pricks to
indicate orientation information.
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Figure 17: Single field phantom:
A) Block with gantry direction indicator
B) Dimensions 14.8 x 14.8 x 16.5 cm3
C) Unassembled single field phantom
D) Single field phantom with top plate removed
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Figure 18: Gantry direction indicator and laser alignment indicators on the single field phantom
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Figure 19: Single field phantom insert

In conducting the single field irradiations, for each field size, we performed four
irradiations. Three measurements were made with TLD micro-cubes, and one measurement was
made with the IROC Houston standard TLD powder capsules. The TLD powder measurement was
used as a reference/ comparison. For each micro-cube irradiation, the cylinder contained 3
micro-cubes (Figure 20 and Figure 21). Each irradiation also used GAFchromic film to check
beam alignment and beam profile. We delivered 600 cGy at 3 field sizes: 10 x 10 cm2, 3 x 3 cm2,
and 2 x 2 cm2 (Figure 22 and Figure 23).
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Figure 20: TLD micro-cube capsule for single field phantom
Dimensions: Diameter= 4.55mm Length= 5.14mm
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Figure 21: TLD micro-cube capsules for single field phantom.

To deliver the radiation dose, we used a 6 MV photon beam from a Varian TrueBeam
linear accelerator, delivered orthogonal to the top face of the phantom block. The block was
oriented towards the gantry using the indications on the block itself (Figure 17A). The source to
surface distance (SSD) was 100 cm, measured with the optical distance indicator. To ensure
congruence of the central axis of the beam with the central axis of the phantom, we aligned the
positioning lasers with the crosshairs of the cylindrical phantom insert (Figure 19). The delivery
setup is pictured in Figure 22.
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Figure 22: Single field irradiation linac set-up.
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Figure 23: Single small field irradiation setup.
A) 10 x 10 cm2
B) 10 x 10 cm2
C) 3 x 3 cm2
D) 2 x 2 cm2

2.6 SRS Head Phantom Irradiation Experiments
To test the efficacy of the micro-cube TLD system, performance was evaluated with
respect to three different treatment delivery systems: Varian TrueBeam Linac, Elekta Gamma
Knife Icon, and Accuray CyberKnife. The treatment planning system used for each machine was
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RayStation 8A, GammaPlan 11.1, and MultiPlan 5.1.2, respectively. Each of these machines are
commonly used to treat brain lesions, and are regularly evaluated by IROC Houston.
For these experiments, an SRS head phantom (Figure 24 and Figure 25) constructed inhouse at IROC Houston was used. IROC Houston uses this phantom to confirm dose and dose
distribution in addition to dose localization in the treatment volume. This portion of the
experiment was designed to show congruence between the current powder TLD system used
for SRS beam evaluation and the micro-cube system.
This head phantom has been used extensively by IROC Houston for end-to-end
evaluations for SRS treatment delivery, and required minor alterations for use with micro-cubes.
The head phantom is constructed of high impact polystyrene. The phantom contains an insert,
held inside of a sleeve, with a solid water sphere (1.9 cm in diameter) which simulates the tumor
volume. Within the tumor volume are two TLD capsules, one superior and one inferior, with the
active TLD powder of each within 0.5 cm of the center of the sphere (Figure 26). The phantom
insert also permits the use of GAFchromic film for dose profile evaluation. The film planes are
orthogonal to each other, in the sagittal and coronal planes of the phantom and pass through
the center of the target sphere (Figure 26). Additionally, the phantom contains three fiducials
for localization and co-registration purposes. The exterior fiducials, indicated by the arrows in
Figure 24, were used for CyberKnife simulation and set-up.
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Figure 24: SRS Head Phantom
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Figure 25: SRS Head Phantom
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Figure 26: Solid water tumor simulator, TLD capsule insert indicated by the blue ovals, and the center of the solid water ball
is indicated by the green crosshairs

When this phantom is sent to an institution or clinic, instructions are included along with
the materials, which give information regarding the prescription. The appendix contains the
instructions for imaging the phantom, treatment planning, and delivery.
For the purposes of this micro-cube experiment, the TLD capsules and some of the
guidelines were slightly altered. Because the dose response of TLD micro-cubes exhibits
supralinearity at high doses, this experiment delivered approximately 600 cGy to the tumor
volume to minimize dose uncertainty. Additionally, the TLD micro-cube capsules (Figure 27),
which replaced the TLD powder, hold three micro-cubes per capsule. We developed treatment
plans that were homogeneous over the treatment volume so each micro-cube would receive
approximately the same dose.
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For each of the three modalities mentioned, four experiments were conducted: one with
the standard IROC Houston TLD-100 powder capsules, and three with TLD-100 micro-cubes. The
purpose of the standard IROC Houston evaluation with TLD powder is for comparison to the
typical phantom results. The work flow for the experiment on each machine included a CT
simulation, development of a treatment plan by a medical physicist, and treatment delivery. In
the following sections, each modality is discussed separately.

Figure 27: SRS micro-cube capsules, constructed with polycarbonate. Each capsule holds 3 TLD micro-cubes.

2.6.1 Varian TrueBeam Treatment Planning and Delivery to SRS Head Phantom
The IROC Houston SRS head phantom was scanned on a Siemens CT scanner, with 1 mm
slice spacing, 530 cm field of view (FOV), and 512 x 512 pixels. The 530 mm FOV accommodates
the couch model used during treatment planning for the linac. Additionally, the phantom was
loaded with “dummy” film and TLD capsules to simulate the treatment volume for appropriate
planning.
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Contours of the “lesion” (Gross Tumor Volume (GTV)), represented by a 1.9 cm sphere
inside the phantom, as well as the two sets of 3 micro-cube TLDs, which were placed near the
center of the sphere (one set is at the inferior-left-anterior, and the other at the superior-rightposterior corner of the center of the sphere), were drawn on RayStation planning based on the
CT scan. The GTV was expanded by 2 mm uniformly in all 3 dimensions to define the Clinical
Target Volume (CTV). The planning goal was to give 600 cGy to the CTV while minimizing the
dose outside CTV. A 6 MV VMAT (Volumetric-modulated Arc Radiotherapy) plan was developed,
with a prescription of 600 cGy to 99% of the GTV with 2 arcs: one clock-wise from gantry angle
182⁰ to 178⁰, and the other counter-clock-wise from 178⁰ to 181⁰. The (min, max, mean) dose
to the CTV, inferior TLD, and superior TLD were (596.7, 609.8, 605.3) cGy, (604.9, 608.2, 605.7)
cGy, and (604.5, 609.4, 607.6) cGy, respectively (Figure 28 and Figure 29).

Figure 28: RayStation treatment planning dose constraint goals
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Figure 29: RayStation treatment planning dose to volume. CTV2mm = Clinical Target Volume, InfTLD = inferior TLD capsule
active volume (powder or micro-cubes), SupTLD = superior TLD capsule active volume.

For treatment delivery, the head phantom was placed on the treatment couch in the
same orientation as the CT simulation. The phantom was loaded with TLD-100 powder capsules,
and GAFchromic film, and aligned using both the wall lasers and light field crosshairs (Figure 30).
Two TLD-100 powder capsules were taped near the ears of the phantom head. This allowed for
subtraction of exposure from onboard images from the measured dose.
The head phantom was then imaged using the Varian TrueBeam cone beam CT (CBCT)
with 1 mm slice spacing. Using this CT, the images were co-registered to attain a 3D-3D match,
and minor couch adjustments were made to ensure optimum accuracy. Masking tape was then
applied to the surface of the head phantom as well as the treatment couch to assist in realignment, as the phantom would have to be removed from the treatment position multiple
times to replace TLD capsules and film for repeated measurements. The treatment plan was
then delivered. This process was repeated three times with TLD-100 micro-cubes and no
reference TLD on the ears, with the assumption that the exposure from each CBCT would be
consistent. Each time an on-board CBCT was taken, the image was co-registered with the
simulation, necessary couch adjustments were made, and treatment was delivered.
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Figure 30: Varian TrueBeam SRS head treatment setup

2.6.2 Elekta Gamma Knife Treatment Planning and Delivery to SRS Head Phantom
The same simulation CT as described in Section 2.6.1, as well as the contours defined in
RayStation for the TrueBeam plan, were imported to GammaPlan to create a treatment plan for
the Gamma Knife machine. In order to give the TLDs 600 cGy, the prescription was set to 400
cGy to the 60% isodose line using 21 composite shots. The (min, max, mean) dose of the CTV,
inferior TLD, and superior TLD were (391,666, 549) cGy, (591, 665, 628) cGy, and (580, 659, 632)
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cGy, respectively. Due to characteristics of Gamma Knife, it is very difficult to get dose coverage
to the CTV when prescribing a plan with isodose lines (IDL) higher than 60%, which would have
resulted in more uniform dose inside CTV.
The phantom was secured inside a mask adaptor using a Moldcare cushion (QFix,
Avondale, Pennsylvania) and Orfit mask (Orfit, Wihnegem, Belgium) for positional
reproducibility between 4 treatments (Figure 31). For the first setup scan, a stand-alone CBCT
acquired without TLDs and films in the phantom, was used as the planning CT, which was
registered to the pre-planned (the original simulation) CT. The final plan was delivered 4 times,
in the same sequence and TLDs/films configuration as the linac deliveries, with the phantom in
the same position as the first CBCT. For each delivery, a treatment-position CBCT was acquired
and registration was reviewed and approved, then treatment was delivered. GammaPlan
automatically adapted the planned shots according to the registration for delivery. The relative
change of the phantom position was presented as a geometrical rotation and translation at the
isocenter, which has coordinates of (x, y, z) = (100, 100, 100) in the Leksell stereotactic space.
The result of these translational and rotational changes of the four deliveries are shown in Figure
32. They were all less than 0.3 degrees (Rotation) and 0.4 mm (translation).
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Figure 31: Gamma Knife setup
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Figure 32: Gamma Knife image co-registration applied correction

Figure 33: Gamma Knife Treatment Plan Dose Map

2.6.3 CyberKnife Treatment Planning and Delivery to SRS Head Phantom
The simulation CT unit used for the CyberKnife treatment planning was a GE LightSpeed
RT 16 (GE Helathcare, USA). The CT used 1.25 mm slice spacing, and 512 x 512 pixels. The images
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were loaded in to MultiPlan 5.1.2 (Accuray Inc., Sunnyvale, CA, Chicago, Illinois) for treatment
planning, using a Sequential Optimization algorithm and Ray Tracing dose calculation algorithm.
Contours were drawn around the 1.9 cm tumor volume, forming the CTV and around the active
volume of both TLD capsules (superior and inferior). Additionally, three gold fiducials, which
were located within the phantom, were identified for phantom positioning during treatment
setup.
The treatment plan was developed to deliver 600 cGy to the 83% isodose line using 46
photon beams (Figure 36). The goal of this treatment plan was to deliver a homogeneous dose
to both capsules. The (min, mean, max) dose to the CTV, inferior capsule (Cap 1), and superior
capsule (Cap 2) were: (582.4cGy, 664.5cGy, 723.0cGy), (658.8cGy, 688.5cGy, 708.9cGy), and
(685.9cGy, 708.3cGy, 723.0cGy), respectively (Figure 34).
To deliver treatment, an Accuray CyberKnife with fixed cones was used. The phantom
head, loaded with ear TLD, TLD capsules, and film, was set on the treatment couch, and roughly
aligned with the wall lasers. This placed the head phantom in the approximate area needed to
take positioning radiographs. These radiographs are taken orthogonally from each other and use
fixed room geometry to determine the position of the phantom in the reference space of the
treatment head. Small adjustments were made to the positioning of the phantom head, and
radiograph images were taken again, until an agreeable position of the phantom was achieved
(approximately three radiographs were taken). The treatment was then delivered to the
phantom head. This process was repeated three more times for a total of four irradiations: one
using TLD powder, and three using TLD micro-cubes.
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Figure 34: Minimum, Mean, and Maximum dose to CTV (Tumor), Inferior TLD Capsule (Cap 1), and Superior Capsule (Cap 2)

Figure 35. TOP: DVH of relative dose BOTTOM: Min, Max, and Mean dose to volumes. Cap 1 = superior capsule Cap 2 =
inferior capsule
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Figure 36: CyberKnife treatment plan. See Appendix
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Figure 37: CyberKnife treatment plan isodose lines to treatment volume. See Appendix

2.7 Single Small Field Irradiations
The purpose of this experiment was to evaluate the limitations of TLD micro-cubes in
measuring small photon fields. An Accuray CyberKnife was used to deliver the photon beams for
the small field experiments. Furthermore, this CyberKnife was used with fixed collimators.
The same single field phantom used for the single field experiments described in section
2.4 was used to hold the TLD capsules. This phantom holds the micro-cubes at Dmax and includes
GAFchromic film for evaluating field alignment. This phantom was set up at 78.5 cm SSD and 80
cm SAD, where the beam output is defined for CyberKnife (Figure 38). The phantom was aligned
using the internal laser of the CyberKnife gantry head (Figure 39).
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The field sizes used in this experiment were 60 20, 15, 10, 7.5, and 5 mm collimator
diameters. Three micro-cubes were used to measure each field size, and each field size was
measured three times.

Figure 38: Small Filed CyberKnife set-up 78.5cm SSD
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Figure 39: CyberKnife internal laser alignment for small field experiments

2.8 TLD Dose Calculations and Dosimetry Evaluation
2.8.1 Dose Calculations
To calculate dose to TLD micro-cubes for the experiments described above, IROC
Houston follows these steps:
1. The TLD standards are irradiated with a Cobalt-60 unit. The dose levels are close to
300 cGy, and 600 cGy (based on the type of session).
2. The standards are read no earlier than 10 days after irradiation.
3. When TLD session begins, a set of standards are read first. Then up to 18 institution
TLD capsules can read followed by another set of controls. Another 18 institution TLD
capsules can be read followed by another set of controls. This is a continued until all
of the TLD sets have been read within a session. A maximum of 54 institution TLD
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capsule could be read in a session. The session is then closed out by a set of standards
being read.
4. Equation 1 is used to determine dose from TLD for photon energies
2.8.2 Film Dosimetry Evaluation
GAFchromic film is used in the IROC Houston QA services in multiple ways. For single field
output dosimetry, the film gives information regarding the alignment of the radiation field with
the central axis of the phantom. For this experiment, alignment is increasingly important at field
sizes below 2 cm x 2 cm, where misalignment can have a serious effect on output at the location
of the micro-cubes. For the SRS head phantoms, the film is used to check phantom alignment
and treatment delivery, as well as an additional check for TLD dose agreement.
Each film used in the single field and SRS head phantom irradiations had pin pricks for
localization. These pin pricks were at known locations within the phantom, which permitted the
evaluation of alignment during film analysis.
Film was read 10 to 14 days after irradiation, which reflects the time post-irradiation in
which film are typically read. It is important to wait a similar time period to read film as the
calibration (Girard, Bouchard, & Lacroix, 2012). To read the film, a Model CCD100 CCD
Microdensitometer

for

Radiochromic

Film

(Photoelectron

Corporation,

Lexington,

Massacheusetts, USA) was used (Figure 40). The image data was then read into a MatLab
program developed by IROC Houston. This program allowed the user to register the pin pricks
to get spatial information about the film (Figure 41). The program calculated a dose map of the
film, which was normalized to the dose from the TLD.
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Following the film registration, the CT images, the radiation therapy dose, plan, and
structures were loaded into the program, co-registered with the film (Figure 42). The
information from the TPS and the film was evaluated for agreement.

Figure 40: Film Densitometer, Model CCD100 CCD Microdensitometer for Radiochromic Film (Photoelectron Corporation,
Lexington, Massachusetts, USA)
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Figure 41: Left: Coronal film loaded using MatLab program Right: Pin breaks registered for positioning, labeled 1, 2, and 3

Figure 42: The film dose profile is co-registered on the CT simulation

2.9 Statistical Analysis
To test our hypotheses regarding the consistency of measured and expected dose for the
various experimental settings, we used a Two One Sided T-Test (TOST) of equivalence. To
perform these t-tests, the tost() function from the equivalence package in R statistical software
was used. The results of the TOST tests were cross checked by running two t-tests using the
t.test() function in R.
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A TOST test was conducted for four sets/populations of measurement in which the values
evaluated were the ratios of measured dose to expected dose. The single field and small field
data were held separately as individual populations. Secondly, the data from all three SRS
modality experiments were combined to form a population. Lastly, the ratio of micro-cube over
powder for both single field and SRS were combined to form the third population to evaluate.
In each of these statistical tests, the composite null hypothesis tested was that the true
ratio was ≤ 0.95 and that the true ratio was ≥ 1.05. With this test, a p-value smaller than 0.05
meant there was strong statistical evidence to reject the null hypotheses, in support that the
true ratio was within the bounds.

3 Results
3.1 Micro-Cube Handling
3.1.1 Micro-Cube Shape Uniformity
We began the experiment with 500 micro-cubes, however, after inspection, we
determined 37 were not suitable for experiments. These were micro-cubes which did not
represent a uniform cubic shape, had chipped edges, or had other apparent malformations
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(Figure 43), and were likely to exhibit poor reproducibility and other complications in TLD
handling.

Figure 43: Irregularly shaped TLD-100 micro-cubes from ThermoScientific

3.1.2 TLD Annealing Response
The analysis of TLD annealing response was described in Section 2.2.2. There was no
noticeable difference in TLD response for leaving TLD in of the oven at 400oC for 10 extra minutes
or leaving the TLD in the oven at 100oC for 30 extra minutes. Nor was there an effect on the TLD
signal output for shortening the cooling phase, however, there was a noticeably large effect on
TLD output when the cooling phase was ignored completely. The decrease in signal output was
29.5% for the group which did not undergo rapid cooling. For the other groups tested with a
different annealing cycle, there was no noticeable difference in TLD output.
This test of annealing response lends confidence that TLD output can be trusted if there
are small changes to annealing, similar to those differences demonstrated here (Figure 44).
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Figure 44: TLD Annealing Response: Legend reads: Time at 400⁰C, Time cooling; Time at 100⁰C

Measurements were also conducted to define the rate of cooling, as it is known that this
portion of annealing can have a significant effect on the output of TLD. The trend in cooling
followed an exponential decay. The temperature reached 60⁰C in just over a minute, and then
gradually decreased to approximately 50⁰C (Figure 45). After this 50° C was reached, there was
no significant decrease in temperature of the annealing planchet for the remainder of the
cooling phase.
It seems that once the temperature has decreased to approximately 50⁰C, the cooling
can be stopped, and the annealing planchet can be moved into the next oven. Given the results
from the experiments in varying annealing times, this seems viable, as decreasing the cooling
period from 5 minutes to 3 minutes did not have an effect on the output of the TLD.
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Figure 45: TLD annealing planchet cooling curve

3.1.3 Micro-Cube Reading Variability
3.1.3.1 Placement Variability
67 micro-cubes were read without specific guidelines on placing the cube in a
reproducible location in the reading planchet. Three repeated measurements of ECF where the
micro-cube was placed as reproducible as possible in the center of the reading planchet were
compared to a single measurement of ECF where the micro-cube was not placed reproducibly.
This variable placement reading increased the average coefficient of variation from 1.2% to
3.0%. The average difference in measured ECF values was 5%, with a maximum of a 15% change
in measured ECF value.
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Figure 46: TLD placement effect

3.1.3.2 Reader Variability
The experiment described above was repeated, however the reader was instructed to
carefully place the TLD in the center of the reading planchet to the best of their ability. The idea
behind this experiment was to gather a perspective on human dependence in evaluating ECF
values. This information gives some insight into reader dependence in reproducibility of
measurements. This experiment showed that the average coefficient of variation increased from
1.1% to 1.5%. Here, the average difference in the measured ECF was 2.1% with a maximum
difference of 5.8%.
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Figure 47: Reader variability

3.2 TLD Micro-cube Characterization
3.2.1 Elemental Correction Factor (ECF)
The average ECF value for 461 micro-cubes was 1.01. Intuitively, the ECF value should be
1, so interest in the result of a 1% difference led to an investigation of this discrepancy. The
response from each batch of micro-cubes is expected to be Gaussian in distribution, symmetric
about the average. In reality, the ECF values more accurately represent a Poisson distribution
(Figure 48), where there is a tail of large ECF values greater than 1, which pushes the average
ECF value above unity. This shows that most of the TLD micro-cubes under-respond to dose,
when compared to the average signal response of all cubes.
To investigate the stability of the individual cubes, the coefficient of variance, defined in
Equation 5, was evaluated for 3 measurements of ECF for each cube. The average coefficient of
variance was 1.25% for 461 micro-cubes where the maximum value was 8.98% and the minimum
was 0.06%.
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For this study, micro-cubes that showed poor reproducibility were banned from use in
further experiments. The cut-off reproducibility was 2%, where any micro-cube with a
coefficient of variance greater than this value was not used. The tolerance for 2% stability is a
stringent request, as TLD micro-cubes have an accuracy of ± 15% (±2 sigma) as specified by
ThermoFisher. Across all TLD cubes, 15.40% of cubes were outside of a 2% coefficient of
variance, which is a larger portion than preferred, but can only be expected when stability is
already stated by the manufacturer as an area of concern. However, only 0.87% were outside of
5%, so if we decided to adopt a looser criteria, a larger proportion of the cubes could be used.

𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝑜𝑜𝑜𝑜 𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉 = 100% ×
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𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷
𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴

Equation 4
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Figure 48: Histogram of ECF values for all TLD micro-cubes.

3.2.2 Linearity Correction Factor (KL)
The linearity correction factor, KL, gives insight as to how TLD-100 micro-cubes respond
to different dose levels. In Figure 49 the TLD signal response versus dose is shown. As expected,
we see a linear dose response to about 400 cGy, and highly correlated linear fit (R-squared value
>0.99).
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Figure 49: TOP) Linearity dose measurement 1 BOTTOM) Linearity measurement 2
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To get actual correction factor KL, the relationship between dose/signal and dose (Figure
50) was analyzed. These curves represent the linearity curves used by IROC Houston for TLD-100
powder. A linear curve was fit to each of the plots, after they were normalized to 600 cGy (Figure
51). For the first measurement, the slope was -1.60 E-4, the intercept was 1.10, and the R2 value
was 0.935. For the second measurement, the slope was -1.95 E-4, the intercept was 1.12, and
the R2 value was 0.913.
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Figure 50: Dose/Signal (KL) with respect to dose. 45A show the first experiment for linearity, while 45B shows the second
experiment.
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Figure 51: Normalized linearity plots. 46A show the first experiment for linearity, while 46B shows the second experiment.

To get the final KL correction factor, the average of the slopes and intercepts was used to
give the equation below, where X is the signal measured from a TLD in nano-Coulombs. A
comparison of the individual slopes is depicted in Figure 52.
𝐾𝐾𝐿𝐿 = −1.774 ∙ 10−4 (𝑛𝑛𝑛𝑛 −1 ) ∙ 𝑋𝑋(𝑛𝑛𝑛𝑛) + 1.106
Equation 9: Measured Linearity Correction Factor
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Figure 52: Linearity correction factors comparison from both measurements

3.2.3 Energy Correction Factor KE
The energy correction factor, KL, was evaluated using Equation 7. The results of the
analysis are in the table below. The energy correction factors for 6 MV photons is about a 4%
correction, 1.036.
Table 4: Energy Correction factors for 60Cobalt, 6MV, and 18MV photon beams.

Energy

KE

60Cobalt

1.0

6 MV

1.036

3.3 Uncertainty Analysis
The uncertainty in both standards and samples is estimated by evaluating the standard
deviation in a large number of readings, irradiated to the same dose. The standard deviation in
the thermoluminescent reading for the samples and the standards were both 0.30%.
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The uncertainty in the dose to the standards, taken from Kirby et al. was 0.60%. This
uncertainty is largely determined by the ion chamber setup uncertainty, taken to be ± 1mm for
both source to chamber distance and the depth of the chamber in water.
The uncertainty in the linearity correction factor was estimated determining the
standard error of the regression coefficient, which is taken from the regression line from the
least-squares fit of the slope of the linearity measurement. Here, the standard error of the
regression coefficient is defined in Equation 12 below. This was determined to be 5.82x10-6 %,
as we evaluated the uncertainty in the correction factor for dose within ± 3% of the 600 cGy
normalization dose.
𝑠𝑠𝐿𝐿2 = [𝑠𝑠𝑏𝑏𝐿𝐿 (𝐷𝐷 − 𝐷𝐷′ )𝑎𝑎𝐿𝐿 /(𝑎𝑎𝐿𝐿 + 𝑏𝑏𝐿𝐿 𝐷𝐷′ )2 ]2

Equation 10

The uncertainty in the energy correction factor stems from a combination in the
uncertainty in the calibration of the photon beam as well as the uncertainty in the TLD readings
themselves. The uncertainty in the energy correction factor was evaluated using Equation 13
below, and was determined to be 7.73x10-3 %.

𝑠𝑠𝐸𝐸2

𝑠𝑠𝐷𝐷′ 2
𝑠𝑠𝑇𝑇
= 𝐾𝐾𝐸𝐸 [2( ′ ) + ( )2 /2]
𝐷𝐷
𝑇𝑇

Equation 11

The uncertainty in the elemental correction factor was estimated from the average
standard deviation of three ECF measurements from all TLD micro-cubes. This standard
deviation was 1.0%.
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Using each of the values described in section 2.3, the total uncertainty in the dose to the
sample was determined to be 1.5%. This value is comparable to the uncertainty in OSLD and TLD
powder used at IROC Houston, which are 1.6% and 1.3% at the one sigma level, respectively
(Alvarez et al., 2017). This 1.5% uncertainty in TLD micro-cube dose determination is well suited
for the ±5% accuracy tolerance that is desired.

3.4 Single Field Experiment Results
The data obtained from single field irradiation experiments is evaluated on agreement
with TLD-100 powder, agreement with the expected beam output, and reproducibility of the
measurements.
The expected beam output and the average measured doses at the location of the TLD
for each field size are shown in Table 5. For each field size, the measurements differed from the
expected dose by less than 4%, with a coefficient of variance of 0.53%, 0.98%, and 0.98% for the
10 x 10 cm2, 3 x 3 cm2, and 2 x 2 cm2 fields, respectively. These results are summarized in Table
5 and Table 6 below.
Table 5: Single field output results

Field Size
(cm2)
10 x 10 A
10 x 10 B
10 x 10 C
3x3A
3x3B
3x3C
2x2A
2x2B
2x2C

Measured Dose
(cGy)
624
623
618
564
558
569
552
554
544

Calculated Dose
(cGy)
602
602
602
548
548
548
536
536
536
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Ratio:
Measured/Expected
1.04
1.03
1.03
1.03
1.02
1.04
1.03
1.03
1.01

% Difference
-3.65%
-3.39%
-2.59%
-2.92%
-1.81%
-3.69%
-3.01%
-3.40%
-1.49%

Table 6: Single filed output average dose, coefficient of variation, and average ratio of measured dose: expected dose

10 x 10 cm2

3 x 3 cm2

2 x 2 cm2

Average Dose (cGy)

622

564

550

Coefficient of Variation

0.53%

0.92%

0.98%

Average Difference from Expected Dose

-3.21%

-2.81%

-2.63%

To compare the results of the TLD micro-cubes to the results measured from the TLD
powder is a final confirmation of the performance of micro-cube in the single field output
experiment. The doses measured for each field size are shown in Table 7. These results agreed
with what the TLD micro-cube measurements by 0.69% on average (Table 7).
Table 7: TLD micro-cube and TLD powder agreement

Field Size
(cm2)
10 x 10
3x3
2x2

TLD MicroCube
(cGy)

622
564
550

TLD Powder
(cGy)

%
Difference
620
-0.28%
563
-0.10%
541
-1.70%

3.4.1 Single Field Film
Film analysis for the 3 x 3 cm2 and 2 x 2 cm2 fields showed that the fields were aligned
well with respect to the single field phantom and the TLD micro-cubes. Below are the field line
profiles for each of the field sizes. All field profiles showed similar results.
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Figure 53: 3 x 3 cm2 field film

Figure 54: 3 x 3 cm2 field line profiles, solid black lines indicate tumor boundaries

Figure 55: 2 x 2 cm2 field film
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Figure 56: 2 x 2 cm2 field line profiles, solid black lines indicate tumor boundaries

3.5 SRS Head Experiment Results
3.5.1 SRS Head Linac Experiment Results
The data for the TrueBeam SRS head phantom experiments was analyzed in multiple
ways. The first was the agreement between the dose measured with the TLD micro-cubes, and
the dose calculated by the TPS. Second was the agreement between what was measured with
the TLD micro-cubes and what was measured with the standard TLD powder. Third was the
reproducibility of the measurements, as the experiment was repeated for a total of three
measurements.
The experiments were identified as A, B, and C, and were further divided into the
superior TLD capsule and the inferior TLD capsule. The expected mean dose to the superior
capsule, as calculated by the TPS was 608 cGy. The average dose measured was 612 cGy, and all
measurements agreed with the expected dose within 1%. For the inferior capsule, the average
dose to the capsule, as calculated by the TPS was 606 cGy, and the average dose measured by
the TLD in the inferior capsule was 605 cGy. All measurements for the inferior capsule were also
within 1% of the expected dose.
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Table 8: Linac SRS head phantom dose measurement compared to TPS doses. Letter A, B, and C refer to the experiment
trial.

Experiment

Measured Dose

Calculated Dose

Ratio:

(cGy)

(cGy)

Measured/Expected

609
612
616
606
609
600

608
608
608
606
606
606

1.00
1.01
1.01
1.00
1.01
0.99

Linac A Superior
Linac B Superior
Linac C Superior
Linac A Inferior
Linac B Inferior
Linac C Inferior

With regards to the reproducibility of these measurements, the average dose to the
superior capsule was 612 cGy, with a coefficient of variance of 0.59%. Second, the average dose
to the inferior capsule as measured by the TLD micro-cubes was 605 cGy, where the coefficient
of variance was 0.76%.

Table 9: Linac micro-cube reproducibility

Average Dose (cGy)
Coefficient of Variation (%)
Average Difference in Expected Dose (%)

Superior Capsule
612
0.59%
-0.79%

Inferior Capsule
605
0.76%
0.15%

Table 10: TLD micro-cube and TLD powder comparison for SRS linac experiments

Capsule

TLD Micro-Cube (cGy)

TLD Powder (cGy)

% Difference

Superior

612

594

-3.10%

Inferior

605

593

-1.99%
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3.5.1.1 SRS Linac Film Analysis
After registering the three pin pricks in each film plane, the software calculated a root
mean square (RMS) error between the expected and actual distance between the registered
points (Figure 57). The MatLab software checks the dose value on a pixel to pixel basis with a
gamma pass/fail criteria of 5% dose difference, and 3mm distance to agreement (DTA). An RMS
error less than 1mm was considered acceptable for use in analysis, which each of the film
registrations met. Once location registration was completed, and the film dose was normalized
to TLD dose, line dose profiles were taken from the film and compared to the TPS calculations
(Figure 58).

Figure 57: SRS linac film registration
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Figure 58: Film dose line profiles for Linac. See appendix for all profiles.

The film was analyzed for agreement between treatment planning system calculated
dose profiles and measured dose profiles. The percent agreement was defined by the gamma
(𝛾𝛾) evaluation (Figure 59). The MatLab software checks the dose value on a pixel to pixel basis
with a gamma pass/fail criteria of 5% dose difference, and 3 mm distance to agreement (DTA).
Films from sagittal and coronal planes for each of the three experiments were registered. From
this data, a mean agreement of 83.6% with a coefficient of variance of 5.4% was obtained (see
Figure 59 for an example, see Appendix for all gamma evaluations).
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Figure 59: Gamma analysis for linac coronal plane

3.5.2 SRS Head Gamma Knife Experiment Results
The data for the Gamma Knife SRS head phantom experiments were analyzed following
the same procedure as the linac data analysis. The average TPS dose to the active volume of the
TLD capsules was 632 cGy and 628 cGy, for the superior and inferior capsules, respectively. The
maximum dose to the active volume was 659 cGy and 665 cGy for the superior and inferior
capsules, respectively.
The measured dose was taken to be the average of the three micro-cubes contained in
the active volume of each capsule. For the superior capsule for experiment A, B, and C, the
average dose to the volume was 618 cGy, 624 cGy, and 610 cGy, respectively. The average
difference between calculated and measured dose to the TLD was 2.39%, where the maximum
difference was 3.55% and the minimum difference was 1.35%. The average dose to the superior
90

capsule was measured to be 617 cGy, with a standard deviation of 6.7 cGy (1.08% coefficient of
variance), for all three measurements.
For the inferior capsule for experiment A, B, and C, the average dose to the volume was
639 cGy, 636 cGy, and 626 cGy respectively. The average difference between calculated and
measured dose to the TLD was 1.14%, where the maximum difference was 1.78% and the
minimum difference was 0.40%. The average dose to the inferior capsule was measured to be
634 cGy, with a standard deviation of 7.2 cGy (1.14% coefficient of variance), for all three
measurements.
Table 11: Summary of Gamma Knife experiment dose calculations. Letter A, B, and C refer to the experiment trial.

Experiment
A Superior
B Superior
C Superior
A Inferior
B Inferior
C Inferior

Measured Dose
(cGy)
618
624
610
639
636
626

Calculated Dose
(cGy)
632
632
632
628
628
628

Ratio:
Measured/Expected
0.98
0.99
0.97
1.02
1.01
1.00

Table 12: Gamma Knife micro-cube reproducibility

Average Dose (cGy)
Coefficient of Variation (%)
Average Difference in Expected Dose (%)

Superior Capsule
617
1.08%

Inferior Capsule
634
1.14%

2.33%

-0.89%

Table 13: TLD micro-cube versus TLD powder for Gamma Knife SRS head experiments

Capsule

TLD Micro-Cube
(cGy)
Superior
617
Inferior
634

TLD Powder
(cGy)
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%
Difference
619
0.28%
649
2.37%

To dive deeper into the analysis of these micro-cubes, the measured dose of the
individual capsules (periphery of tumor volume, middle cube, and center of tumor volume) was
reviewed. The dose of Gamma Knife treatments were inhomogeneous within the treatment
volume, and there were hotspots over the active volume of the TLD micro-cube capsule (Figure
60 and Figure 61). In Figure 60, there is a visible hotspot of 650 cGy towards the periphery of the
simulated tumor volume, local to the active volume of the TLD capsule. This 650 cGy hotspot
encompasses the location of the outermost micro-cube. Likewise, there is a similar hotspot in
the region of the inferior capsule. Figure 61 shows this 650 cGy hotspot also near the periphery
of the tumor volume, in the vicinity of the active volume of the TLD capsule. This region high
dose encompasses the most inferior micro-cube.
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Active volume of
capsule

Active volume of
capsule

Figure 60: Superior Capsule
TOP: Axial view
BOTTOM: Sagittal View
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Active volume of
capsule

Active volume of
capsule

Figure 61: Inferior Capsule
TOP: Axial View
BOTTOM: Sagittal View
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For the superior and inferior TLD capsules, the micro cubes are designated as “periphery
of tumor”, “middle cube” and “center of tumor”. For the superior capsule, the average measured
dose to the periphery, middle, and center micro-cubes was 627 cGy, 619 cGy, and 606 cGy,
respectively, where the coefficient of variance was 0.65%, 1.49%, and 1.27% for the three
measurements. The calculated dose to the superior periphery, middle, and center micro-cubes
was 650, 630, and 620 cGy respectively. For the inferior capsule, the average measured dose to
the periphery, middle, and center micro-cubes was 649 cGy, 640 cGy, and 611 cGy, respectively,
where the coefficient of variance was 1.18%, 2.21%, and 1.83% for the three measurements.
The calculated dose to the inferior periphery, middle, and center micro-cubes was 660, 640, and
620 cGy, respectively. The data regarding these measurements is shown in Table 14 below.

Dose W/ Respect to Capsule Placement
660
650

Dose(cGy)

640

Periphery of Tumor Superior

630

Middle of Capsule Superior

620

Center of Tumor Superior
Periphery of Tumor Inferior

610

Middle of Capsule Inferior

600
590

Center of Tumor Inferior
0

1

2

3

4

5

TLD Location
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6

7

Table 14: TLD micro-cube differences in Gamma Knife experiment

Superior Capsule
Average Dose to Superior Periphery (cGy)
627

Inferior Capsule
Average Dose to Inferior Periphery (cGy)
649

Superior Periphery Coefficient of
Variance (%)
0.65%
Average Ratio in Expected Dose
0.96
Average Dose to Superior Middle (cGy)
619
Superior Middle Coefficient of Variance
(%)
1.49%
Average Ratio in Expected Dose
0.98
Average Dose to Superior Center (cGy)
620
Superior Center Coefficient of Variance
(%)
1.24%
Average Ratio in Expected Dose
0.98

Superior Periphery Coefficient of
Variance (%)
1.18%
Average Ratio in Expected Dose
0.98
Average Dose to Inferior Middle (cGy)
640
Inferior Middle Coefficient of Variance (%)
2.21%
Average Ratio in Expected Dose
1.00
Average Dose to Inferior Center (cGy)
611
Inferior Center Coefficient of Variance (%)
1.83%
Average Ratio in Expected Dose
0.99

3.5.2.1Gamma Knife Film Analysis
After registering the three pin pricks in each film plane, an RMS error less than 1mm was
considered acceptable, and each film registration achieved this requirement. Once location
registration was completed, and the film dose was normalized to TLD dose, line dose profiles
were taken from the film and compared to the TPS calculations (Figure 64).
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Figure 62: Film registration using 3 pin breaks for localization in the coronal plane

Figure 63: Film dose line profiles for Gamma Knife. See appendix for all profiles.

The film was analyzed for agreement between treatment planning system calculated
dose profiles and measured dose profiles. The percent agreement was defined by the gamma
(𝛾𝛾) evaluation (Figure 65). Films from sagittal and coronal planes for each of the three
experiments were registered. From this data, a mean agreement of 98.94% with a coefficient of
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variance of 0.35% was obtained (see Figure 65 for an example, see Appendix for all gamma
evaluations).

Figure 64: Film and TPS dose agreement

3.5.3 SRS Head CyberKnife Experiment Results
The data collected from the SRS CyberKnife experiments was evaluated on the same
bases as the linac and Gamma Knife experiments. Agreement between TPS and micro-cube, TLD
powder and micro-cube, and reproducibility were all considered. The expected dose as
calculated by the TPS was 708 cGy to the superior TLD capsule, and 689 cGy to the inferior. The
average measured dose to the superior capsule was 705 cGy, where the maximum difference in
calculated to measured dose was 0.80% and the minimum was 0.13%. The average measured
dose to the inferior capsule was 684 cGy, where the maximum difference in measured and
calculated dose was 1.92% and the minimum difference was 0.05%. The difference between the
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average measured dose and the calculated dose was 0.43% and 0.70% for the superior and
inferior TLD capsules respectively. These results are contained in Table 15 and Table 16 below.

Table 15: CyberKnife measured dose evaluation

CyberKnife Experiment
A Superior
B Superior
C Superior
A Inferior
B Inferior
C Inferior

Measured Dose
(cGy)
709
704
703
675
687
689

Calculated Dose (cGy)
708
708
708
689
689
689

Ratio:
Measured/Expected
1.00
0.99
0.99
0.98
1.00
1.00

Table 16: CyberKnife experiment reproducibility

Average Dose (cGy)
Coefficient of Variation (%)
Average Difference in Expected Dose (%)

Superior Capsule
705
0.49%
0.43%

Inferior Capsule
684
1.07%
0.70%

Table 17: Comparison of micro-cube and TLD powder

Capsule

TLD Micro-Cube
(cGy)
Superior
705
Inferior
684

TLD Powder
(cGy)

%
Difference
699
-0.90%
637
-7.32%

3.5.3.1 CyberKnife film Analysis
Similar to the first two SRS experiments described, after registering the three pin pricks
in each film plane, an RMS error less than 1mm was considered acceptable, and each film
registration achieved this requirement. Once location registration was completed, and the film
dose was normalized to TLD dose, line dose profiles were taken from the film and compared to
the TPS calculations (Figure 67).
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Figure 65: CyberKnife film registration in the sagittal plane

Figure 66: CyberKnife film line profiles

The film was analyzed for agreement between treatment planning system calculated
dose profiles and measured dose profiles. The percent agreement was defined by the gamma
(𝛾𝛾) evaluation (Figure 65). The MatLab software checks the dose value on a pixel to pixel basis
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with a gamma pass/fail criteria of 5% dose difference, and 3mm distance to agreement (DTA).
Films from sagittal and coronal planes for each of the three experiments were registered. From
this data, a mean agreement of 96.37% with a coefficient of variance of 0.78% was obtained
(Figure 68).

Figure 67: Gamma analysis for CyberKnife SRS experiments

3.6 Single Small Field Output Results
The average dose in cGy measured by the micro-cubes for the 60, 20, 15, 10, 7.5, and 5
mm fields was 594, 575, 559, 529, 498, and 411 respectively. The calculated dose for these fields
were 600, 589, 572, 540, 514, and 428 cGy for the respective fields.
For the 60 mm field, the average ratio of measured dose to calculated dose is 0.99. The
maximum and minimum difference in measured and calculated dose is 1.22% and 0.17%, where
the coefficient of variance of the measurements is 0.67%. For the 20 mm field, the average ratio
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of measured dose to calculated dose is 0.98. The maximum and minimum difference in
measured and calculated dose is 2.95% and 1.90%, where the coefficient of variance of the
measurements is 0.61%. For the 15 mm field, the average ratio of measured dose to calculated
dose is 0.98. The maximum and minimum difference in measured and calculated dose is 2.49%
and 1.91%, where the coefficient of variance of the measurements is 0.32%.
For the 10 mm field, the average ratio of measured dose to calculated dose is 0.98. The
maximum and minimum difference in measured and calculated dose is 2.24% and 1.58%, where
the coefficient of variance for the measurements is 0.37%.For the 7.5 mm field, the average ratio
of measured dose to calculated dose is 0.97. The maximum and minimum difference in
measured and calculated dose is 13.69% and 2.66%, where the coefficient of variance for the
measurements is 0.56%. Finally, for the 5 mm field, the average ratio of measured dose to
calculated dose is 0.97. The maximum and minimum difference in measured and calculated dose
is 3.63% and 3.25%, where the coefficient of variance for the measurements is 0.21%.
These results are contained in the tables below:
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Table 18: Single small field irradiation results

Field size
60 mm A

Measured Dose
(cGy)
593

Calculated
Dose (cGy)
600

Ratio
Measured/Expected
0.99

60 mm B

592

600

0.99

60 mm C

592

600

1.00

20 mm A

577

589

0.98

20 mm B

571

589

0.97

20 mm C

577

589

0.98

15 mm A

558

572

0.98

15 mm B

558

572

0.98

15 mm C

561

572

0.98

10 mm A

528

540

0.98

10 mm B

528

540

0.98

10 mm C

532

540

0.98

7.5 mm A

495

514

0.96

7.5 mm B

499

514

0.97

7.5 mm C

500

514

0.97

5 mm A

414

428

0.97

5 mm B

413

428

0.96

5 mm C

412

428

0.96

Table 19: Single small field irradiation results

Field Size
Average Dose(cGy)
Coefficient of Variance (%)
Average Difference from Expected Dose

60 mm
594
0.67%
0.93%

20 mm
575
0.61%
2.26%

15 mm
560
0.32%
2.27%

10 mm
529
0.37%
2.00%

7.5 mm
498
0.56%
3.07%

5 mm
413
0.21%
3.49%

3.6.1 Small Field Film
Similar to the single field film data, there did appear to be a 1 mm shift inferiorly (away
from the gantry) in the line profiles, which could have an effect on measured output of the fields
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smaller than 15 mm. Figure 69 below depicts the film for field sizes 20 mm and smaller. Figure
70 shows the line profile for the 5 mm cone for Cyberknife small field irradiations. Figures for
other field sizes are located in the appendix.

Figure 68: A) 20 mm B) 15 mm C) 10 mm D) 7.5 mm E) 5 mm
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Figure 69: 5 mm field line profile, the thick vertical lines represent the boundaries of the micro cubes

3.7 Statistical Analysis
For each of the four populations, ((1) single field, n=9 (2), SRS experiments, n=18, (3) TLD
micro-cube vs. TLD powder, n=8, and (4) small field, n=18), a TOST test of equivalence on the
ratio of measured to expected dose was performed to assess statistical confidence that the
ratios were within the equivalence bounds. A p-value of 6.72E-5, 7.34E-12, 6.3E-5, and 4.54E-10
was obtained for the respective populations, all showing statistical significance of the
consistency of the measurements with expected values.
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4 Discussion
4.1 Characterization
The values obtained for energy correction and linearity are similar to those which IROC
Houston obtained for TLD-100 powder, although it is difficult to compare the correction factors
for micro-cubes with powder. Not only are they different forms of TLD, but characterization of
TLD is done on a batch-to-batch basis, so correction factors are expected to be somewhat
different.

4.2 TLD Handling and Reading
The manner in which micro-cubes are handled and used is directly correlated with the
performance they are able to achieve. Factors such as maintaining identity of each cube,
annealing protocol, and careful reading placement of micro-cubes have a direct effect on
measurements. Additionally, careful handling of the micro-cubes themselves is quite important.
In the experience gained from this work, using tweezers and jeweler’s glasses to handle the
micro-cubes is necessary for manipulating micro-cubes with the dexterity needed for placing
them in the reading planchet, as well as the frequent transfers from annealing trays to SRS and
single field capsules. While tweezers are necessary to use, they add a risk of scratching the
surface of the cubic faces, or chipping them from force used. If it is possible to file or coat the
tips of the tweezers, that is recommended. Additionally, consistency in the reading technique of
trained readers is a factor to be considered, as TLD placement is vital in obtaining reliable results.
There are multiple factors that must be considered in executing a successful micro-cube
process. Implementing micro-cubes into a quality assurance program requires that these factors
be carefully defined and adhered to in order to obtain satisfactory results.
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4.3 Irradiation Experiments
4.3.1 Single Field Irradiations
When analyzing the accuracy of the single field experiments, all measurements for all
three field sizes were within 4.1% of the documented beam output. The reproducibility showed
a coefficient of variance of 0.81% was achieved. These data points are within the bounds for ±5%
accuracy and ±3% reproducibility.
What these results suggest is that the measurements were systematically higher than
expected. For the 10 x 10 cm2 field, the average ratio of measured dose over calculated dose
was 1.04± 0.01. For the 3 x 3 cm2 field, the average ratio of measured dose over calculated dose
was 1.03± 0.01. Lastly, for the 2 x 2 cm2 field, the average ratio of measured dose over calculated
dose was 1.03 ± 0.01. These measurements show very good reproducibility, but the dose is
further from the beam output dose than is expected, and repeatedly so. These output
measurements were confirmed by the TLD-100 powder measurements, which are well trusted.
In this experiment the difference in TLD micro-cube and TLD powder for 10 x 10, 3 x 3, and 2 x 2
cm2 fields were 0.28%, 0.10%, and 1.70%, respectively. These results lead us to believe that the
beam output for this linac was possibly 3 to 4% higher than documented, and that the measured
results were valid. A review of the last annual machine output check by IROC Houston also
showed a measurement that was several percent high, so these results follow the machine
history.
4.3.2 SRS Linac, Gamma Knife, CyberKnife Experiments
For the SRS Linac experiments, all three measurements for the superior capsule and
inferior capsules were within 1.4% of the TPS calculated dose. These measurements were
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performed on a different linac than the one use for the single field output checks. In this
experiment, the coefficient of variance of the superior and inferior capsule measurements was
0.59% and 0.76%, respectively. These results were well within the ±5% accuracy and ±3%
reproducibility aims. Additionally, the agreement between the TLD micro-cube and TLD powder
for this experiment was 3.1% and 2.0% for the superior and inferior capsules, respectively.
For the SRS Gamma Knife experiments, all three measurements for the superior capsule
and inferior capsules were within 3.43% of the TPS calculated dose. In this experiment, the
coefficient of variance for the superior and inferior capsule measurements was 1.08% and
1.14%, respectively. These results were within our aims of ±5% accuracy and ±3% reproducibility.
Additionally, the agreement between the TLD micro-cube and TLD powder for this experiment
was 0.28% and 2.4% for the superior and inferior capsules, respectively.
Lastly, for the SRS CyberKnife experiments, all three measurements for the superior
capsule and inferior capsules were within 1.9% of the TPS calculated dose. In this experiment,
the coefficient of variance for the superior and inferior capsule measurements was 0.49% and
1.07%, respectively. These results were within our aims of ±5% accuracy and ±3% reproducibility.
Additionally, the agreement between the TLD micro-cube and TLD powder for this experiment
was 0.90% and 7.3% for the superior and inferior capsules, respectively. The inferior capsule for
powder measurements seems to be an outlier and is likely not an accurate measurement. An
explanation for this could be that the capsule was reversed in the phantom, placing the powder
outside of the treatment volume where the dose would agree. Regardless, no conclusion drawn
from this single measurement would be valid.
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For all SRS head phantom experiments, both our accuracy and reproducibility were
within the aims of the experiment and showed very good agreement with TPS calculations and
powder measurements.
4.3.3 Small Field Irradiations
The small field irradiation experiments embodied the goals of this thesis, as they helped
to define the limitations and capabilities of micro-cube TLD. All other experiments in this thesis
have been conducted using TLD powder, however, the smallest field size typically used for TLD
powder is a 12.5 mm field. This small field experiment tested 4 fields small than this.
The measurements for small field irradiations were all within 3.69% of the documented
beam output for the CyberKnife. The coefficient of variance for the 60, 20, 15, 10, 7.5, and 5 mm
fields were all less than 0.67%, showing excellent reproducibility. This final test of the capabilities
of micro-cube TLD showed that measurements were within the aims of ±5% accuracy and ±3%
reproducibility.
A note regarding the smaller field sizes of this experiment: the ability to align the
phantom perfectly under the central axis of the beam is of utmost importance. In looking at the
films collected from these experiments, there appears to be a slight offset of a little less than
one millimeter, which would be within the tolerance for CyberKnife laser alignment with the
beam central axis (<1 mm). This likely explains the systematic under response of approximately
3% in the 7.5 mm and 5 mm fields, where the dose fall-off is quite sharp away from central axis.
4.3.4 Film Analysis
The main objective of film analysis is to evaluate alignment of the treatment plan with
the actual treatment itself. In this sense, the most important information we gather from film
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analysis is the line profiles with respect to the TPS line profiles. These gives us alignment
information. The gamma analysis gives some further insight, however there are limitations to
gamma analysis. In this work, this was particularly apparent in the linac SRS head experiments
where the agreement was only 84%, which was much lower than expected. This is a result of
noise in the treatment and film, and is not an indication of poor delivery or planning. The beam
output shows very good agreement and the film profile distance-to-agreement is also very good,
so we put more weight in those characteristics for this analysis.

4.4 Statistics
A p-value smaller than 0.05 indicates strong statistical evidence to reject the null
hypothesis, which for each TOST test was that the true ratio was ≤0.95 and that the true ratio

was ≥ 1.05 i.e. the result was outside of a ±5% accuracy bound. Because each p-value was much
smaller than 0.05, we can confidently conclude that the TLD micro-cubes are capable of accuracy
within ±5%.

4.5 Small Field Considerations
An item of concern in small field dosimetry is the level of care needed in making
irradiations. In this experiment, this particular consideration can be exemplified in the small field
experiments of 1.5 cm and smaller. By looking at the dose profile (Figure 71), it is easy to see
that a small shift off of central axis could result in a largely reduced output due to the extremely
steep fall off of the beam. Essentially, there is no flat region of the beam that is sometimes seen
in larger fields, and thus the likelihood of misalignment is increased substantially.
This may be evident in our own experiments where extreme care was taken in aligning
the phantom with the central axis. It seems that our phantom placements were just a fraction
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of a millimeter off axis, and this could be the reason for our systematic measurement under
response of 3%.
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Figure 70: 5 mm field profile of CyberKnife

5 Conclusion
5.1 Conclusion
The aim of this study was to develop a remote dosimetry audit system using TLD microcubes to evaluate small radiation fields. More specifically, the hypothesis of this work was:
Micro-cube TLD can be commissioned to evaluate small field dosimetry, and provide
reproducibility within ±3%, as well as assure agreement between measured dose and calculated
doses to within ±5%.
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The first two experiments conducted in this work, single field output measurements and
SRS head phantom measurements, served as an evaluation to answer the question: Can TLD
micro-cubes perform as well as TLD powder and show equivalence in measurements?
Intrinsically, if the micro-cubes could not show equivalence to TLD powder in these two audit
test that are already implemented, then there could be little confidence that they would show
promising results in small field dosimetry. Fortunately, the TLD micro-cubes did show close
agreement with the TLD powder in each experiment. This gave confidence in the potential of
the micro-cubes.
However, the backbone of this work was truly in the small field experiments. TLD powder
and OSLD chips have been used extensively in the single field output checks and SRS head
phantom measurements, and there is no reason to use micro-cubes to make these
measurements. The novelty in this work is to define the limits of micro-cubes in small field
dosimetry. This meant evaluating fields smaller than the 1.25 cm limit placed on TLD powder
measurements.
This experiment proved, with confidence, that TLD micro-cubes can evaluate field sizes
as small as 5 mm in diameter. For the CyberKnife, this is the smallest field size available. These
measurements collected in the experiments surpassed the expectations of the hypothesis,
showing that TLD micro-cubes are an appropriate tool for small field dosimetry. Additionally, the
system developed proved effectively robust, allowing it to be implemented as an audit program.
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5.2 Future Work

5.2.1 Fading Correction
One item that was not completed in this study was characterization of the fading
correction factor. Because the standards defining reader system sensitivity and the experimental
micro-cubes were both irradiated and read on the same day in each experiment, the fading
correction factor was unnecessary. However, if this system is to be implemented as an audit
program, it is unlikely that the standards and experimental micro-cubes will be irradiated on the
same day. In this light, a fading correction factor for micro-cubes should be measured.
5.2.2 Future Applications
This study has shown the capabilities of TLD micro-cubes and opens a door to their
routine use. One such avenue is in SRS head phantoms. A future application of TLD micro-cubes
is to develop an SRS head phantom in which the simulated tumor volume is smaller than the
current 1.9 cm. This would be a unique application of the micro-cubes, and would allow an audit
of smaller targets for SRS.
A similar application would be to develop an SRS head phantom with multiple targets, as
opposed to a single target in the center of the cranial region. This would be a more robust and
inclusive audit for SRS treatments and likely more practical to SRS treating multiple brain
metastases.
These applications of TLD micro-cubes are not only novel, but very applicable to a
comprehensive SRS audit program. They would serve as a complete evaluation of possible
treatments for brain metastasis to provide insight for institutions, aiding in the improvement of
treatment delivery.
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6 Appendix
6.1 SRS Head Phantom Instructions
Imaging the Phantom:
1.

If you use immobilization, apply it on the phantom. For headframes, the target is located
roughly between the upper parts of the ears. When positioning the phantom, please
attempt to keep the head level and straight so that the mid-coronal and mid-sagittal film
planes are not rotated (if applicable to your setup, two leveling screws are present on the
base-plate of the phantom). This is optimal to compare these measured planes with the
corresponding dose plane produced by your treatment planning system.

2.

Locate the target with CT. This phantom is not compatible with MRI imaging and if MRI
imaging is desired a different (water-filled) SRS phantom is necessary. Please provide axial,
coronal and sagittal images through the target volume when submitting data to IROC.

3.

Create a treatment plan according to the guidelines provided below.

Treatment Planning:
1. The target is the solid water ball that should be evident on the CT scan. The center of the ball
defines the center of the target volume. Please treat the solid water ball as the PTV.
2. Contour the TLD powder inside both of the capsules. The powder is illustrated in the figure
below. Please note that the powder is just the high contrast volume near the mid-plane of
the insert – please do not include the capsule plugs in this contour (the TLD powder size is
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approximately 3 mm in diameter and 4 mm in length). Submit the TLD contour dose as
determined by your treatment planning computer. Please also submit the point dose to the
center of the TLD.

3. Plan a treatment that covers the target volume while sparing all other tissues. To achieve
maximum precision, IROC would like the dose to the center of the target to be approximately
30Gy (100% isodose line). This should be achievable with the following dose guidelines:
a. GammaKnife: Cover the target with 15 Gy (prescription isodose line 40% - 60%)
b. CyberKnife: Cover the target with 20 Gy (prescription isodose line 60% - 80%)
c. C-arm linear accelerator: Cover the target with 25 Gy (prescription isodose line >85%)
Treatment
1.

Align the phantom according to your clinical workflow.

2.

Remove the ear TLD after imaging is complete and before treatment begins.

3.

Irradiate the phantom according to your plan.
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6.2 Gamma Knife
6.2.1 Gamma Knife Treatment Plan Snapshots
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6.2.2 Gamma Knife Dose Profile

6.2.3 GammaKnife Film

Figure 71 Gamma Knife coronal plane film registration
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Figure 72 Gamma Knife sagittal plane film registration

6.2.4 Gamma Knife Film Gamma Analysis

Figure 73 Gamma Knife A Coronal
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Figure 74 Gamma Knife A sagittal

Figure 75 Gamma Knife B coronal
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Figure 76 Gamma Knife B sagittal

Figure 77 Gamma Knife C coronal
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Figure 78 Gamma Knife C sagittal

6.2.5 Gamma Knife Film/TPS dose Line Profiles
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6.3 CyberKnife
6.3.1 CyberKnife Treatment Plan Snapshots
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6.3.2 CyberKnife Film

Figure 79: CyberKnife Coronal Film
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Figure 80: CyberKnife Sagittal Film

6.3.3 CyberKnife Film Gamma Analysis

Figure 81. Coronal A
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Figure 82. Sagittal A

Figure 83. Coronal B
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Figure 84. Sagittal B

Figure 85. Coronal C
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Figure 86. Sagittal C
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6.3.4 CyberKnife Film/TPS dose Agreement
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6.4 Linac
6.4.1 Linac Treatment Plan Snapshots and Isodose Lines
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6.4.2 Linac Film

Figure 87: Linac Coronal Film

Figure 88: Linac Sagittal Film
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6.4.3 Linac Film Gamma Analysis

Figure 89: Linac Coronal A

Figure 90: Linac Sagittal A
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Figure 91: Coronal B

Figure 92: Sagittal A
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Figure 93: Coronal C

Figure 94: Sagittal C
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6.4.3 Linac Film/TPS dose Line Profiles
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6.5 Small Field Film Line Profiles
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